L’ACMTS tient à appuyer les décideurs du secteur de la santé canadiens durant cette période difficile et incertaine.
Pour trouver des outils, ressources et données probantes touchant la COVID-19, consultez notre portail sur la COVID-19.
Cette page résume l’état d’avancement des examens en vue du remboursement d’un médicament de l’ACMTS. Quiconque peut chercher, consulter, télécharger ou imprimer gratuitement les rapports à des fins non commerciales ou à des fins de recherche ou d’étude, pourvu que le contenu soit utilisé tel quel et que l’ACMTS soit dument mentionnée.
| Marque de commerce | Nom générique | Indication | Recommendation Type | État d'avancement du projet | Présentation reçue | Date d'émission de la recommandation |
|---|---|---|---|---|---|---|
| Rituxan | Rituximab | Leucémie Leucémie aigüe lymphoblastique |
Date d’émission de l’avis de mise en application | February 13, 2017 | August 31, 2017 | |
| Avastin | Bevacizumab | Gynécologique Ovarian Cancer |
Date d’émission de l’avis de mise en application | November 28, 2014 | June 4, 2015 | |
| Halaven | Eribulin Mesylate | Breast Metastatic Breast Cancer |
Date d’émission de l’avis de mise en application | February 9, 2012 | August 2, 2012 | |
| Imbruvica | Ibrutinib | Leucémie Leucémie lymphoïde chronique / petit lymphome lymphocytaire (n’ayant jamais été traité) |
Date d’émission de l’avis de mise en application | April 20, 2016 | ||
| Jakavi | Ruxolitinib | Other Polycythemia vera |
Date d’émission de l’avis de mise en application | August 27, 2015 | March 3, 2016 | |
| Kyprolis | Carfilzomib | Myélome Myélome multiple (en rechute) |
Date d’émission de l’avis de mise en application | September 9, 2016 | ||
| Blincyto (Reconsidération) | Blinatumomab | Leucémie Leucémie aigüe lymphoblastique (LAL) chez l’adulte |
Date d’émission de l’avis de mise en application | February 24, 2017 | August 31, 2017 | |
| Votrient | Pazopanib hydrochloride | Genitourinary Metastatic renal cell carcinoma |
Date d’émission de l’avis de mise en application | July 14, 2011 | January 5, 2012 | |
| Treanda | Bendamustine hydrochloride | Leukemia chronic lymphocytic leukemia (CLL) |
Date d’émission de l’avis de mise en application | April 24, 2012 | November 29, 2012 | |
| Afinitor | Everolimus | Gastrointestinal Pancreatic neuroendocrine tumours |
Date d’émission de l’avis de mise en application | February 27, 2012 | August 30, 2012 | |
| Zytiga | Abiraterone acetate | Genitourinary Metastatic Castration Resistant Prostate Cancer |
Date d’émission de l’avis de mise en application | March 28, 2013 | October 22, 2013 | |
| Onivyde | Irinotécan liposomal | Gastro-intestinal Cancer du pancréas métastatique |
Date d’émission de l’avis de mise en application | April 27, 2017 | January 5, 2018 | |
| Inlyta | Axitinib | Génito-urinaire Hypernéphrome métastatique |
Date d’émission de l’avis de mise en application | April 18, 2017 | ||
| Proleukin | Aldesleukin (IL-2) | Peau et mélanome In-transit Melanoma |
Date d’émission de l’avis de mise en application | January 30, 2015 | June 22, 2015 | |
| Revlimid | Lenalidomide | Myeloma Multiple Myeloma |
Date d’émission de l’avis de mise en application | April 5, 2013 | October 22, 2013 | |
| Sylvant | Siltuximab | Lymphoma Multicentric Castleman's Disease (MCD) |
Date d’émission de l’avis de mise en application | January 30, 2015 | June 22, 2015 | |
| Treanda | Bendamustine hydrochloride | Leukemia Chronic lymphocytic leukemia (First Line) |
Date d’émission de l’avis de mise en application | April 24, 2012 | February 19, 2013 | |
| Vectibix | Panitumumab | Gastrointestinal Metastatic Colorectal Cancer |
Date d’émission de l’avis de mise en application | April 15, 2015 | December 3, 2015 | |
| Votrient | Pazopanib hydrochloride | Genitourinary Metastatic Renal Cell Carcinoma |
Notification to Implement Issued Original Submission Complete | February 20, 2013 | August 29, 2013 | |
| Xalkori | Crizotinib | Lung Cancer du poumon non à petites cellules avancé |
Notification to Implement Issued Original Submission Complete | March 26, 2012 | October 4, 2012 | |
| Avastin | Bevacizumab | Gynécologique Platinum-Resistant Ovarian Cancer |
Date d’émission de l’avis de mise en application | October 29, 2015 | May 5, 2016 | |
| Cyramza | Ramucirumab | Lung Non-Small Cell Lung Cancer |
File-Closed Not Submitted | |||
| Pomalyst | Pomalidomide | Myélome Myélome multiple (deuxième intention) |
Date d’émission de l’avis de mise en application | March 15, 2019 | September 18, 2019 | |
| Mvasi | Bévacizumab | Gastro-intestinale/poumon Cancer colorectal métastatique/biosimilaire contre le cancer du poumon non à petites cellules |
Final Biosimilar Dossier Issued | October 3, 2018 | ||
| Xalkori | Crizotinib | Poumon Cancer du poumon non à petites cellules ROS1-positif avancé |
Date d’émission de l’avis de mise en application | October 30, 2018 | May 23, 2019 | |
| Xtandi | Enzalutamide | Génito-urinaire Cancer de la prostate non métastatique résistant à la castration |
Date d’émission de l’avis de mise en application | September 24, 2018 | March 26, 2019 | |
| Imfinzi | Durvalumab | Poumon Cancer du poumon non à petites cellules |
Date d’émission de l’avis de mise en application | September 21, 2018 | May 3, 2019 | |
| Blincyto | Blinatumomab | Leucémie Leucémie lymphoblastique aigüe (LLA) à précurseurs B et chromosome Philadelphie positif (Ph+) |
Date d’émission de l’avis de mise en application | August 31, 2018 | April 4, 2019 | |
| Tagrisso | Osimertinib | Poumon Cancer du poumon non à petites cellules (première intention) |
Date d’émission de l’avis de mise en application | May 16, 2018 | January 4, 2019 | |
| Lutathera | Lutétium Lu 177 dotatate | Gastro-intestinal Tumeurs neuroendocrines gastroentéropancréatiques |
Date d’émission de l’avis de mise en application | July 30, 2018 | August 1, 2019 | |
| Beleodaq | Bélinostat | Lymphome Lymphome T périphérique |
Withdrawn | June 29, 2018 | ||
| Cabométyx | Cabozantinib | Génito-urinaire Carcinome rénal avancé |
Date d’émission de l’avis de mise en application | September 17, 2018 | February 20, 2019 | |
| Adcetris | Brentuximab védotine | Lymphome et myélome Lymphome hodgkinien présentant un risque élevé de récidive ou de progression après une greffe autologue de cellules souches (GACS). |
Date d’émission de l’avis de mise en application | August 10, 2017 | February 21, 2018 | |
| Besponsa | Inotuzumab ozogamicine | Leucémie Leucémie aigüe lymphoblastique (LAL) |
Final Recommendation Posted | November 13, 2017 | July 6, 2018 | |
| Revlimid | Lénalidomide | Myélome Myélome multiple |
Date d’émission de l’avis de mise en application | June 19, 2019 | ||
| Nerlynx | Nératinib | Sein Cancer du sein à récepteurs hormonaux positifs |
Date d’émission de l’avis de mise en application | April 18, 2019 | December 5, 2019 | |
| Libtayo | Cémiplimab | Peau et mélanome Carcinome épidermoïde cutané |
Date d’émission de l’avis de mise en application | July 9, 2019 | January 22, 2020 | |
| Xtandi | Enzalutamide | Génitourinaire Cancer de la prostate métastatique sensible à la castration (CPMSC) |
Final Recommendation Posted | February 24, 2020 | September 23, 2020 | |
| Kisqali | Ribociclib | Sein Cancer du sein au stade avancé ou métastatique |
Date d’émission de l’avis de mise en application | August 26, 2019 | June 4, 2020 | |
| Inqovi | décitabine-cédazuridine | Leucémie syndrome myélodysplasique (SMD) |
Under Review | October 9, 2020 | ||
| À déterminer | Entrectinib | Autre Tumeurs solides présentant une fusion du gène récepteur tyrosine kinase neurotrophique (NTRK) |
Withdrawn | July 29, 2019 | ||
| Keytruda | Pembrolizumab | Génitourinaire Carcinome à cellules rénales |
Date d’émission de l’avis de mise en application | August 2, 2019 | April 2, 2020 | |
| Adcetris | Brentuximab védotine | Lymphome Lymphome anaplasique à grandes cellules cutané primitif ou mycosis fongoïde exprimant CD30 |
Under Review | March 30, 2020 | ||
| Lynparza | Olaparib | Sein Le traitement du cancer du sein métastatique sans surexpression du récepteur 2 du facteur de croissance épidermique humain (HER2-négatif) chez la patiente adulte porteuse d’une mutation germinale délétère ou présumée délétère d’un gène BRCA ayant déjà reçue une chimiothérapie néoadjuvante ou adjuvante ou une chimiothérapie en contexte de maladie métastatique. |
Not Filed | |||
| Keytruda | Pembrolizumab | Tête et cou carcinome épidermoïde de la tête et du cou (CETC) |
Under Review | May 1, 2020 | ||
| Keytruda | Pembrolizumab | Gastrointestinal En monothérapie dans le traitement de l'adulte atteint de cancer colorectal inopérable ou métastatique associé à une forte instabilité microsatellitaire ou à une déficience du système de réparation des mésappariements, caractérisé par une tumeur ayant progressé après un traitement par une fluoropyrimidine, l’oxaliplatine et l’irinotécan. |
Not Filed | |||
| Bavencio | Avélumab | génitourinaire carcinome urothélial |
Under Review | September 18, 2020 | ||
| Zejula | Niraparib | Gynécologie Cancer de l'ovaire |
Under Review | September 21, 2020 | ||
| Lynparza | Olaparib | génitourinaire cancer de la prostate résistant à la castration métastatique (CPRCm) |
Under Review | September 22, 2020 | ||
| Tafinlar et Mekinist | Dabrafénib et tramétinib | Poumon cancer du poumon non à petites cellules exprimant une mutation V600 du gène BRAF |
Under Review | October 1, 2020 | ||
| Blincyto | Blinatumomab | Leucémie Leucémie aigüe lymphoblastique à précurseurs B avec maladie résiduelle minime |
Final Recommendation Posted | January 20, 2020 | October 29, 2020 | |
| Keytruda | Pembrolizumab | Génito-urinaire Carcinome urothélial métastatique |
Final Recommendation Posted | July 24, 2017 | March 2, 2018 | |
| Opdivo | Nivolumab | Lung Non-Small Cell Lung Cancer |
Date d’émission de l’avis de mise en application | October 29, 2015 | June 3, 2016 | |
| Sarclisa | Isatuximab | Myélome Myélome multiple |
Under Review | August 17, 2020 | ||
| Afinitor | Everolimus | Breast Advanced Breast Cancer |
Date d’émission de l’avis de mise en application | September 5, 2012 | March 25, 2013 | |
| Yervoy | Ipilimumab | Peau et mélanome First Line Advanced Melanoma |
Date d’émission de l’avis de mise en application | August 15, 2014 | December 22, 2014 | |
| Ninlaro | Ixazomib | Myélome Myélome multiple |
Final Recommendation Posted | December 16, 2016 | June 29, 2017 | |
| Opdivo | Nivolumab | Tête et cou Cancer épidermoïde de la tête et du cou |
Date d’émission de l’avis de mise en application | January 31, 2017 | August 31, 2017 | |
| Avastin | Bevacizumab | Poumon Mésothéliome pleural malin |
Withdrawn | December 16, 2016 | ||
| Treanda | Bendamustine hydrochloride | Lymphoma Non-Hodgkin lymphoma (NHL) |
Date d’émission de l’avis de mise en application | April 24, 2012 | November 29, 2012 | |
| Velcade | Bortezomib | Myeloma Multiple Myeloma |
Date d’émission de l’avis de mise en application | October 29, 2012 | March 25, 2013 | |
| Zaltrap | Aflibercept | Gastrointestinal Metastatic Colorectal Cancer |
Date d’émission de l’avis de mise en application | November 26, 2013 | September 5, 2014 | |
| Onivyde | Nanoliposomal irinotecan | Gastro-intestinal Cancer du pancreas métastatique |
File-Closed Not Submitted | |||
| Lynparza (nouvelle demande) | Olaparib | Gynécologique Cancer de l’ovaire |
Date d’émission de l’avis de mise en application | March 17, 2017 | September 20, 2017 | |
| Avastin (with capecitabine) | Bevacizumab | Gastrointestinal Metastatic Colorectal Cancer |
Date d’émission de l’avis de mise en application | February 18, 2015 | July 21, 2015 | |
| Darzalex | Daratumumab | Myélome Myélome multiple |
Date d’émission de l’avis de mise en application | April 21, 2016 | December 1, 2016 | |
| Giotrif | Afatinib | Lung Advanced Non Small Cell Lung Cancer |
Date d’émission de l’avis de mise en application | June 7, 2013 | May 2, 2014 | |
| Ibrance | Palbociclib | Sein Cancer du sein avancé |
Suspended | November 11, 2015 | ||
| Imbruvica | Ibrutinib | Leukemia Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (previously treated) |
Date d’émission de l’avis de mise en application | August 15, 2014 | March 5, 2015 | |
| Zydelig | Idelalisib | Leukemia Chronic Lymphocytic Leukemia |
Date d’émission de l’avis de mise en application | April 7, 2015 | August 18, 2015 | |
| Kyprolis (avec lénalidomide) | Carfilzomib (avec lénalidomide) | Myélome Myélome multiple |
Date d’émission de l’avis de mise en application | December 11, 2015 | June 21, 2016 | |
| Lynparza | Olaparib | Gynécologique Cancer de l'ovaire |
Date d’émission de l’avis de mise en application | April 1, 2016 | September 29, 2016 | |
| Opdivo | Nivolumab | Génitourinaire Carcinome métastatique des cellules rénales |
Date d’émission de l’avis de mise en application | February 24, 2016 | September 1, 2016 | |
| Stivarga (CRC) | Regorafenib | Gastrointestinal Metastatic Colorectal Cancer |
Date d’émission de l’avis de mise en application | March 22, 2013 | November 15, 2013 | |
| Tafinlar | Dabrafenib | Peau et mélanome Metastatic Melanoma |
Date d’émission de l’avis de mise en application | March 18, 2013 | December 5, 2013 | |
| Venclexta en association au Rituximab | Venetoclax | Leucémie Leucémie lymphoïde chronique (LLC) |
Date d’émission de l’avis de mise en application | October 24, 2018 | May 31, 2019 | |
| Opdivo | Nivolumab | Gastro-intestinale Carcinome hépatocellulaire (CHC) |
Date d’émission de l’avis de mise en application | May 8, 2018 | November 29, 2018 | |
| Unituxin | Dinutuximab | Neurologique Neuroblastome |
Date d’émission de l’avis de mise en application | October 1, 2018 | March 26, 2019 | |
| Blincyto | Blinatumomab | Leucémie Leucémie lymphoblastique aigüe à précurseurs B avec maladie résiduelle minimale |
Withdrawn | June 29, 2018 | ||
| À déterminer | Abemaciclib | Sein Cancer du sein avancé ou métastatique |
Date d’émission de l’avis de mise en application | December 3, 2018 | July 5, 2019 | |
| Keytruda | Pembrolizumab | Poumon Carcinome bronchopulmonaire non à petites cellules |
Date d’émission de l’avis de mise en application | September 14, 2018 | May 31, 2019 | |
| À déterminer | Rituximab | Lymphome et leucémie Lymphome non-hodgkinien et leucémie lymphoïde chronique - biosimilaire |
File-Closed Not Submitted | |||
| Gazyva | Obinutuzumab | Lymphome Lymphome folliculaire non traité auparavant |
Date d’émission de l’avis de mise en application | March 15, 2018 | November 1, 2018 | |
| Cabometyx | Cabozantinib | Gastrointestinal Carcinome hépatocellulaire |
Date d’émission de l’avis de mise en application | October 16, 2019 | April 22, 2020 | |
| Lonsurf | Trifluridine-tipiracil | Gastrointestinal Cancer gastrique |
Final Recommendation Posted | September 3, 2019 | March 24, 2020 | |
| Mylotarg | Gemtuzumab ozogamicin | Leucémie Leucémie myéloïde aigüe |
Date d’émission de l’avis de mise en application | August 9, 2019 | April 2, 2020 | |
| Imbruvica | Ibrutinib | Leucémie En association avec rituximab dans le traitement des patients non précédemment traités atteints de leucémie lymphoïde chronique (LLC)/ lymphome à petits lymphocytes (LPL); en association avec obinutuzumab dans le traitement des patients non précédemment traités atteints de leucémie lymphoïde chronique (LLC)/ lymphome à petits lymphocytes (LPL) |
Not Filed | |||
| Kadcyla | Trastuzumab emtansine | Sein Cancer du sein au stade précoce |
Date d’émission de l’avis de mise en application | July 2, 2019 | January 22, 2020 | |
| Odomzo | Sonidegib | Peau et mélanome Carcinome basocellulaire |
Under Review | June 19, 2020 | ||
| Rozlytrek | Entrectinib | Poumon Cancer du poumon non à petites cellules porteur de la mutation ROS1 |
Under Review | January 8, 2020 | ||
| Opdivo en combinaison avec Yervoy | Nivolumab en combinaison avec ipilimumab | Poumon cancer du poumon non à petites cellules (CPNPC) |
Under Review | June 23, 2020 | ||
| Calquence | Acalabrutinib | Leucémie Leucémie lymphoïde chronique (LLC) |
Open for Feedback on Recommendation | April 7, 2020 | ||
| Ninlaro | Ixazomib | Myélome Traitement du myélome multiple (2e intention ou plus) |
Date d’émission de l’avis de mise en application | November 30, 2018 | July 5, 2019 | |
| Perjeta et Herceptin en association | Pertuzumab et trastuzumab en association | Sein Cancer du sein au stade précoce |
Date d’émission de l’avis de mise en application | April 9, 2018 | November 29, 2018 | |
| Adcetris (reconsidération) | Brentuximab védotine | Lymphome Lymphome de Hodgkin |
Date d’émission de l’avis de mise en application | August 27, 2018 | March 7, 2019 | |
| Tafinlar et Mekinist en association | Dabrafénib et tramétinib en association | Peau et mélanome Traitement adjuvant du mélanome |
Date d’émission de l’avis de mise en application | September 21, 2018 | May 3, 2019 | |
| Vizimpro | Dacomitinib | Poumon Cancer du poumon non à petites cellules |
Date d’émission de l’avis de mise en application | September 19, 2018 | May 31, 2019 | |
| Faslodex | Fulvestrant | Sein Cancer du sein localement avancé ou métastatique |
Date d’émission de l’avis de mise en application | July 17, 2017 | February 1, 2018 | |
| Erbitux | Cétuximab | Gastro-intestinal Cancer colorectal gauche métastatique |
File-Closed Not Submitted | |||
| Tafinlar & Mekinist en combinaison | Dabrafénib & Tramétinib en combinaison | Poumon Cancer du poumon non à petites cellules |
Date d’émission de l’avis de mise en application | March 31, 2017 | November 2, 2017 | |
| Bavencio | Avélumab | Peau et mélanome Carcinome à cellules de Merkel métastatique |
Date d’émission de l’avis de mise en application | October 10, 2017 | March 21, 2018 | |
| Erbitux | Cetuximab | Gastrointestinal Metastatic Colorectal Cancer |
Date d’émission de l’avis de mise en application | June 10, 2013 | January 10, 2014 | |
| Ibrance (Reconsidération) | Palbociclib | Sein Cancer du sein avancé |
Date d’émission de l’avis de mise en application | June 10, 2016 | November 21, 2016 | |
| Imbruvica | Ibrutinib | Lymphome Macroglobulinémie de Waldenström |
Date d’émission de l’avis de mise en application | April 21, 2016 | November 3, 2016 | |
| Kadcyla | Trastuzumab emtansine | Breast Metastatic Breast Cancer |
Date d’émission de l’avis de mise en application | March 15, 2013 | January 10, 2014 | |
| Lenvima | Lenvatinib | Endocrine Cancer de la thyroïde différencié |
Date d’émission de l’avis de mise en application | April 18, 2016 | September 20, 2016 | |
| Treanda (in combination with rituximab) | Bendamustine hydrochloride | Leukemia Chronic Lymphocytic Leukemia |
Withdrawn | June 27, 2014 | ||
| Votrient | Pazopanib Hydrochloride | Sarcoma Soft Tissue Sarcoma (STS) |
Date d’émission de l’avis de mise en application | June 4, 2012 | November 29, 2012 | |
| Xtandi | Enzalutamide | Genitourinary First Line Metastatic Castration-Resistant Prostate Cancer |
Date d’émission de l’avis de mise en application | October 2, 2014 | June 22, 2015 | |
| Mekinist | Trametinib | Peau et mélanome Metastatic Melanoma |
Date d’émission de l’avis de mise en application | May 6, 2013 | October 22, 2013 | |
| Perjeta Herceptin Combo Pack | Pertuzumab | Breast Metastatic Breast Cancer |
Date d’émission de l’avis de mise en application | November 2, 2012 | August 1, 2013 | |
| Stivarga (GIST) | Regorafenib | Other Gastrointestinal Stromal Tumours |
Date d’émission de l’avis de mise en application | October 11, 2013 | May 2, 2014 | |
| Tafinlar & Mekinist in combo | Dabrafenib & Trametinib in combo | Peau et mélanome Metastatic Melanoma |
Date d’émission de l’avis de mise en application | February 13, 2015 | July 21, 2015 | |
| Venclexta | Venetoclax | Leucémie Leucémie lymphoïde chronique |
Open for Feedback on Recommendation | July 8, 2016 | ||
| Adcetris | Brentuximab védotine | Lymphome Lymphome de Hodgkin (LH) après autogreffe de cellules souches (AGCS) |
Withdrawn | April 5, 2016 | ||
| Blincyto | Blinatumomab | Leukemia Acute Lymphoblastic Leukemia |
Date d’émission de l’avis de mise en application | August 24, 2015 | April 1, 2016 | |
| Cotellic | Cobimetinib | Peau et mélanome Mélanome métastatique |
Date d’émission de l’avis de mise en application | December 11, 2015 | June 30, 2016 | |
| Alimta | Pemetrexed | Lung Advanced Non-Squamous Non Small Cell Lung Cancer |
Date d’émission de l’avis de mise en application | May 31, 2013 | November 19, 2013 | |
| À déterminer | Cabozantinib | Génito-urinaire Carcinome rénal |
Withdrawn | October 6, 2017 | ||
| Zejula | Niraparib | Gynécologique Cancer de l’ovaire |
Date d’émission de l’avis de mise en application | February 7, 2020 | September 3, 2020 | |
| Tecentriq et Avastin | atézolizumab et bévacizumab | Gastro-intestinal Carcinome hépatocellulaire (CHC) |
Open for Feedback on Recommendation | May 21, 2020 | ||
| Ogivri | Trastuzumab | Sein/gastro-intestinal Traitement du cancer du sein au stade précoce/cancer du sein métastatique/cancer gastrique métastatique |
Withdrawn | December 18, 2018 | ||
| Alecensaro | Alectinib | Poumon Cancer du poumon non à petites cellules localement avancé ou métastatique (traitement de deuxième intention) |
Date d’émission de l’avis de mise en application | August 18, 2017 | March 29, 2018 | |
| Erleada | Apalutamide | Génitourinaire Cancer de la prostate métastatique sensible à la castration |
Date d’émission de l’avis de mise en application | October 15, 2019 | April 22, 2020 | |
| Daurismo | Glasdegib | Leucémie leucémie aiguë myéloblastique |
Open for Feedback on Recommendation | May 6, 2020 | ||
| Keytruda | Pembrolizumab | Poumon Cancer du poumon non à petites cellules (première intention) |
Date d’émission de l’avis de mise en application | December 12, 2016 | August 23, 2017 | |
| Atriance | Nélarabine | Leucémie Leucémie lymphoblastique aigüe (LLA) |
File-Closed Not Submitted | |||
| Bosulif (DA) | Bosutinib | Leucémie Leucémie myéloïde chronique |
Date d’émission de l’avis de mise en application | April 8, 2019 | ||
| Lynparza | Olaparib | Gynécologie Cancer des ovaires |
Date d’émission de l’avis de mise en application | April 18, 2019 | December 5, 2019 | |
| Idhifa | Énasidénib | Leucémie Leucémie myéloïde aigüe (LMA) |
Date d’émission de l’avis de mise en application | October 31, 2019 | ||
| Keytruda | Pembrolizumab | Génito-urinaire Carcinome urothélial métastatique (première intention) |
Date d’émission de l’avis de mise en application | February 20, 2019 | October 3, 2019 | |
| Zytiga (Reconsidération) | Abiratérone | Génito-urinaire Cancer de la prostate |
Suspended | July 29, 2019 | ||
| Oncaspar | Pégaspargase | Leucémie Leucémie aigüe lymphoblastique (LAL) chez l'adulte |
Not Filed | |||
| Xospata | Giltéritinib | Leucémie Leucémie aigüe myéloblastique (LAM) |
Date d’émission de l’avis de mise en application | October 28, 2019 | May 20, 2020 | |
| À déterminer | Trastuzumab | Sein et gastro-intestinal Cancer du sein et de l'estomac - biosimilaire |
File-Closed Not Submitted | |||
| Tecentriq | Atézolizumab | Sein Cancer du sein triple négatif (CSTN) avancé ou métastatique |
Withdrawn | October 2, 2019 | ||
| Adcetris | Brentuximab védotine | Lymphome Lymphome T périphérique (LTP) |
Date d’émission de l’avis de mise en application | October 8, 2019 | June 4, 2020 | |
| Nubeqa | Darolutamide | Génito-urinaire Cancer de la prostate non métastatique résistant à la castration |
Date d’émission de l’avis de mise en application | August 27, 2019 | April 22, 2020 | |
| Abraxane | Nab paclitaxel | Gastrointestinal Metastatic Pancreatic Cancer |
Date d’émission de l’avis de mise en application | February 14, 2014 | September 23, 2014 | |
| Adcetris | Brentuximab vedotin | Lymphoma Systemic Anaplastic Large Cell Lymphoma |
Date d’émission de l’avis de mise en application | March 15, 2013 | December 5, 2013 | |
| Arzerra | Ofatumumab | Leukemia Chronic Lymphocytic Leukemia |
Date d’émission de l’avis de mise en application | April 14, 2014 | January 29, 2015 | |
| Rydapt | Midostaurin | Leucémie Leucémie myéloblastique aigüe |
Date d’émission de l’avis de mise en application | June 12, 2017 | December 19, 2017 | |
| Afinitor | Everolimus | Endocrinien Tumeurs neuroendocrines d’origine gastrointestinale ou pulmonaire |
Date d’émission de l’avis de mise en application | May 30, 2016 | December 1, 2016 | |
| Bosulif | Bosutinib | Leukemia Chronic Myeloid Leukemia |
Date d’émission de l’avis de mise en application | May 30, 2014 | April 21, 2015 | |
| Opdivo + Yervoy en association | Nivolumab + Ipilimumab en association | Peau et mélanome Mélanome métastatique |
Date d’émission de l’avis de mise en application | November 30, 2016 | November 30, 2017 | |
| Keytruda | Pembrolizumab | Lymphome et myélome Lymphome de Hodgkin classique |
Date d’émission de l’avis de mise en application | July 7, 2017 | January 5, 2018 | |
| Alecensaro | Alectinib | Poumon Cancer du poumon non à petites cellules (première intention) |
Date d’émission de l’avis de mise en application | January 15, 2018 | July 25, 2018 | |
| Trisenox | Arsenic Trioxide | Leukemia Acute Promyelocytic Leukemia |
Date d’émission de l’avis de mise en application | August 30, 2013 | February 18, 2014 | |
| Yondelis | Trabectédine | Sarcome Liposarcome ou léiomyosarcome métastatique |
Date d’émission de l’avis de mise en application | December 22, 2015 | August 5, 2016 | |
| Xalkori | Crizotinib | Lung Advanced Non-Small Cell Lung Cancer |
Notification to Implement Issued Original Submission Complete | October 23, 2012 | May 2, 2013 | |
| Xalkori | Crizotinib | Lung First Line ALK Positive Advanced NSCLC |
Date d’émission de l’avis de mise en application | February 17, 2015 | July 21, 2015 | |
| Blincyto | Blinatumomab | Leucémie Leucémie aigüe lymphoblastique (LAL) pédiatrique |
Date d’émission de l’avis de mise en application | February 24, 2017 | August 23, 2017 | |
| Stivarga | Régorafénib | Gastro-intestinal Carcinome hépatocellulaire inopérable |
Date d’émission de l’avis de mise en application | October 12, 2017 | April 18, 2018 | |
| Venclexta | Vénétoclax | Leucémie Leucémie lymphoïde chronique |
Final Recommendation Posted | July 10, 2017 | March 2, 2018 | |
| Erivedge | Vismodegib | Peau et mélanome Advanced Basal Cell Carcinoma |
Date d’émission de l’avis de mise en application | June 14, 2013 | January 10, 2014 | |
| Iclusig | Ponatinib | Leukemia Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia |
Date d’émission de l’avis de mise en application | March 13, 2015 | October 1, 2015 | |
| Inlyta | Axitinib | Genitourinary Metastatic Renal Cell Carcinoma |
Date d’émission de l’avis de mise en application | August 16, 2012 | March 7, 2013 | |
| Jakavi | Ruxolitinib | Other Myelofibrosis |
Date d’émission de l’avis de mise en application | June 25, 2012 | January 14, 2013 | |
| Keytruda | Pembrolizumab | Peau et mélanome Metastatic Melanoma |
Date d’émission de l’avis de mise en application | April 16, 2015 | November 16, 2015 | |
| Nexavar | Sorafenib | Endocrine Metastatic Progressive Differentiated Thyroid Carcinoma (DTC) |
Date d’émission de l’avis de mise en application | December 19, 2014 | July 16, 2015 | |
| Perjeta or Perjeta-Herceptin Combo Pack | Pertuzumab | Breast Neoadjuvant Breast Cancer |
Date d’émission de l’avis de mise en application | December 19, 2014 | July 16, 2015 | |
| Stivarga Resubmission (CRC) | Regorafenib | Gastrointestinal Metastatic Colorectal Cancer |
Date d’émission de l’avis de mise en application | December 19, 2014 | July 16, 2015 | |
| Tagrisso | Osimertinib | Poumon Cancer du poumon non à petites cellules |
Date d’émission de l’avis de mise en application | April 1, 2016 | May 4, 2017 | |
| Alecensaro | Alectinib | Poumon Cancer du poumon non à petites cellules |
Date d’émission de l’avis de mise en application | October 3, 2016 | May 4, 2017 | |
| Gazyva | Obinutuzumab | Lymphome Lymphome folliculaire |
Date d’émission de l’avis de mise en application | November 4, 2016 | June 2, 2017 | |
| Cyramza | Ramucirumab | Gastrointestinal Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma |
Date d’émission de l’avis de mise en application | April 15, 2015 | October 29, 2015 | |
| Folotyn | Pralatrexate | Lymphome Lymphome T périphérique |
Date d’émission de l’avis de mise en application | June 1, 2018 | April 4, 2019 | |
| Opdivo | Nivolumab | Peau et mélanome Traitement d’appoint du mélanome |
Date d’émission de l’avis de mise en application | August 27, 2018 | March 7, 2019 | |
| Rydapt | Midostaurin | Autre Mastocytose systémique |
Date d’émission de l’avis de mise en application | August 13, 2019 | April 2, 2020 | |
| Imbruvica | Ibrutinib | Lymphome En association avec rituximab dans le traitement la macroglobulinémie de Waldenström |
Not Filed | |||
| Darzalex | Daratumumab | Myélome Myélome multiple (nouvellement diagnostiqué) |
Date d’émission de l’avis de mise en application | January 4, 2019 | August 29, 2019 | |
| Truxima | Rituximab | Lymphome et leucémie Dans le traitement du lymphome non hodgkinien et de la leucémie lymphoïde chronique - biosimilaire |
File-Closed Not Submitted | |||
| Keytruda | Pembrolizumab | Peau et mélanome Traitement adjuvant du mélanome |
Date d’émission de l’avis de mise en application | December 13, 2018 | August 1, 2019 | |
| Zytiga | Abiratérone | Génitourinaire Cancer de la prostate |
Withdrawn | February 25, 2019 | ||
| Opdivo et Yervoy | Nivolumab et ipilimumab | Poumon mésothéliome pleural malin |
En attente | |||
| Demylocan | Décitabine | Autre Syndromes myélodysplasiques |
File-Closed Not Submitted | |||
| Alunbrig | Brigatinib | Poumon Traitement du cancer du poumon non à petites cellules (CPNPC) |
Date d’émission de l’avis de mise en application | December 5, 2018 | August 1, 2019 | |
| Lenvima | Lenvatinib | Gastrointestinal Carcinome hépatocellulaire |
Date d’émission de l’avis de mise en application | February 8, 2019 | July 24, 2019 | |
| Keytruda | Pembrolizumab | gynécologique En monothérapie dans le traitement des adultes atteints de cancer de l’endomètre inopérable ou métastatique associé à une forte instabilité microsatellitaire ou à une déficience du système de réparation des mésappariements, caractérisé par une tumeur ayant progressé après un traitement et qui ne peut être traitée d’aucune autre manière acceptable. |
Not Filed | |||
| Polivy | polatuzumab védotine | Lymphome lymphome diffus à grandes cellules B (LDGCB) |
Under Review | September 29, 2020 | ||
| Alunbrig | Brigatinib | Poumon cancer du poumon non à petites cellules exprimant la kinase du lymphome anaplasique |
Under Review | September 30, 2020 | ||
| Tecentriq et Avastin | Atézolizumab et bévacizumab | Poumon Carcinome pulmonaire non à petites cellules non épidermoïde |
Date d’émission de l’avis de mise en application | November 18, 2019 | July 3, 2020 | |
| Darzalex | Daratumumab | Myélome multiple Myélome |
Date d’émission de l’avis de mise en application | July 17, 2019 | March 5, 2020 | |
| Unituxin | dinutuximab | neurologique neuroblastome chez l’enfant |
En attente | |||
| Venclexta | Venetoclax Obinutuzumab | Leucémie leucémie lymphoïde chronique (LLC) |
Open for Feedback on Recommendation | April 17, 2020 | ||
| Kisqali | Ribociclib | Sein Cancer du sein métastatique ou avancé |
Date d’émission de l’avis de mise en application | October 17, 2017 | April 18, 2018 | |
| Adcetris | Brentuximab vedotin | Lymphoma Hodgkin Lymphoma |
Date d’émission de l’avis de mise en application | March 14, 2013 | August 29, 2013 | |
| Avastin | Bevacizumab | Gynécologique Cervical Cancer |
Date d’émission de l’avis de mise en application | October 27, 2014 | March 23, 2015 | |
| Caprelsa | Vandétanib | Endocrine Cancer médullaire de la thyroïde |
Date d’émission de l’avis de mise en application | August 15, 2016 | March 30, 2017 | |
| Zykadia | Céritinib | Poumon Cancer du poumon non à petites cellules |
Final Recommendation Posted | June 5, 2015 | March 21, 2017 | |
| Gazyva | Obinutuzumab | Leukemia Chronic Lymphocytic Leukemia |
Date d’émission de l’avis de mise en application | August 11, 2014 | January 27, 2015 | |
| Imbruvica | Ibrutinib | Lymphome Lymphome du manteau |
Date d’émission de l’avis de mise en application | January 29, 2016 | July 19, 2016 | |
| Zydelig | Idelalisib | Lymphome Lymphome folliculaire |
Date d’émission de l’avis de mise en application | April 12, 2016 | September 29, 2016 | |
| Keytruda | Pembrolizumab | Poumon Cancer du poumon non à petites cellules (2e intention et suivantes) |
Date d’émission de l’avis de mise en application | April 21, 2016 | November 3, 2016 | |
| Opdivo | Nivolumab | Peau et mélanome Metastatic Melanoma |
Date d’émission de l’avis de mise en application | August 13, 2015 | April 1, 2016 | |
| Pomalyst | Pomalidomide | Myeloma Multiple Myeloma |
Date d’émission de l’avis de mise en application | January 13, 2014 | July 31, 2014 | |
| Revlimid | Lenalidomide | Myeloma Multiple Myeloma (newly diagnosed) |
Date d’émission de l’avis de mise en application | May 4, 2015 | December 3, 2015 | |
| Sutent | Sunitinib malate | Gastrointestinal Pancreatic neuroendocrine tumours |
Date d’émission de l’avis de mise en application | November 7, 2011 | May 3, 2012 | |
| Zelboraf | Vemurafenib | Peau et mélanome Advanced Melanoma |
Date d’émission de l’avis de mise en application | December 6, 2011 | June 1, 2012 | |
| Darzalex | Daratumumab | Myélome Myélome multiple (deuxième intention et au-delà) |
Date d’émission de l’avis de mise en application | March 3, 2017 | October 5, 2017 | |
| Xtandi | Enzalutamide | Genitourinary Metastatic Castration Resistant Prostate Cancer |
Date d’émission de l’avis de mise en application | March 4, 2013 | July 23, 2013 | |
| Tykerb (in combination with Letrozole) | Lapatinib | Breast Metastatic Breast Cancer |
Date d’émission de l’avis de mise en application | December 14, 2012 | July 5, 2013 | |
| Yervoy | Ipilimumab | Peau et mélanome Advanced Melanoma |
Date d’émission de l’avis de mise en application | December 1, 2011 | April 18, 2012 | |
| Zykadia (Reconsidération) | Céritinib | Poumon Cancer du poumon non à petites cellules |
Date d’émission de l’avis de mise en application | October 19, 2016 | March 21, 2017 | |
| Zevalin | Ibritumomab tiuxétan | Lymphome Lymphome non hodgkinien (LNH) |
Not Filed | |||
| Vectibix | Panitumumab | Gastro-intestinal Cancer colorectal gauche métastatique |
Date d’émission de l’avis de mise en application | September 8, 2017 | March 29, 2018 | |
| Ibrance | Palbociclib | Sein Cancer du sein avancé ou métastatique |
Date d’émission de l’avis de mise en application | September 28, 2018 | May 3, 2019 | |
| Erleada | Apalutamide | Génito-urinaire Cancer de la prostate réfractaire à l’orchidectomie |
Date d’émission de l’avis de mise en application | April 16, 2018 | November 1, 2018 | |
| Lonsurf | Trifluridine et tipiracil | Gastro-intestinal Cancer colorectal métastatique |
Final Recommendation Posted | November 6, 2017 | July 6, 2018 | |
| Opdivo en association avec Yervoy | Nivolumab en association avec ipilimumab | Génito-urinaire Adénocarcinome rénal |
Date d’émission de l’avis de mise en application | April 26, 2018 | November 1, 2018 | |
| Lartruvo | Olaratumab | Sarcome Sarcome avancé des tissus mous |
Date d’émission de l’avis de mise en application | October 26, 2017 | April 18, 2018 | |
| Opdivo | Nivolumab | Lymphome et myélome Lymphome de Hodgkin classique n’ayant pas répondu à une GACS |
Date d’émission de l’avis de mise en application | September 29, 2017 | May 3, 2018 | |
| Tecentriq | Atézolizumab | Poumon Cancer du poumon non à petites cellules |
Date d’émission de l’avis de mise en application | December 15, 2017 | June 20, 2018 | |
| Lenvima | Lenvatinib | Génito-urinaire Hypernéphrome |
Date d’émission de l’avis de mise en application | June 8, 2018 | January 4, 2019 | |
| Kisqali | Ribociclib combiné au fulvestrant | Sein Cancer du sein au stade avancé ou métastatique |
Date d’émission de l’avis de mise en application | August 26, 2019 | April 22, 2020 | |
| Lorbrena | Lorlatinib | Poumon Cancer du poumon non à petites cellules (CPNPC) |
Date d’émission de l’avis de mise en application | June 11, 2019 | January 30, 2020 | |
| Lonsurf | Trifluridine et tipiracil | Gastrointestinal Cancer colorectal métastatique |
Date d’émission de l’avis de mise en application | January 21, 2019 | August 29, 2019 | |
| Tecentriq | Atézolizumab | Poumon Cancer du poumon à petites cellules (CPPC) |
Date d’émission de l’avis de mise en application | March 4, 2019 | January 30, 2020 | |
| Vitrakvi | Larotrectinib | Autre Tumeurs solides métastatiques ou de stade avancé présentant une fusion du gène NTRK (Neurotrophic Tyrosine Receptor Kinase) |
Date d’émission de l’avis de mise en application | February 25, 2019 | October 31, 2019 | |
| Keytruda | Pembrolizumab | Poumon Cancer du poumon non à petites cellules (CPNPC) squameux |
Date d’émission de l’avis de mise en application | February 8, 2019 | January 3, 2020 | |
| À déterminer | Bévacizumab | Gastrointestinal/Poumon Cancer colorectal métastatique; cancer du poumon non à petites cellules |
File Closed | March 14, 2019 | ||
| Inrebic | fédratinib | Autre Myélofibrose |
En attente | |||
| Calquence | Acalabrutinib | leucémie Leucémie lymphoïde chronique (jamais encore traitée) |
Open for Feedback on Recommendation | April 7, 2020 | ||
| Adcetris | brentuximab védotine | Lymphome Le traitement du lymphome de Hodgkin de stade IV en combinaison avec la doxorubicine, la vinblastine et la dacarbazine |
Under Review | April 2, 2020 | ||
| Vitrakvi | larotrectinib | Autre Neurotrophic Tyrosine Receptor Kinase |
Open for Input on Submission | |||
| Istodax | Romidepsin | Lymphoma Peripheral T-Cell Lymphoma |
Date d’émission de l’avis de mise en application | December 1, 2014 | May 19, 2015 | |
| Gynazole.1 | Nitrate de butoconazole | Infection vaginale | Do not list | Complete | June 30, 2004 | January 26, 2005 |
| NovoMix 30 | Insuline asparte et protamine d'insuline asparte | Diabète sucré | Do not list | Complete | October 13, 2005 | April 26, 2006 |
| Fosavance 70/5600 | Alendronate monosodique et cholécalciférol | Ostéoporose | List in a similar manner to other drugs in class | Complete | December 18, 2008 | June 17, 2009 |
| Abilify | Aripiprazole | Schizophrénie | Do not list | Complete | November 6, 2009 | April 27, 2010 |
| Abilify | Aripiprazole | Dépression, trouble dépressif majeur (TDM) | Do not list | Complete | October 1, 2013 | October 22, 2014 |
| Abilify | Aripiprazole | Schizophrénie et troubles psychotiques connexes | List with clinical criteria and/or conditions | Complete | March 29, 2011 | July 18, 2011 |
| Abilify Maintena | Aripirazole | Schizophrénie | List with criteria/condition | Complete | January 6, 2014 | December 19, 2014 |
| Abstral | Citrate de fentanyl | Douleur, cancer (accès douloureux) | Do not list | Complete | June 30, 2011 | December 16, 2011 |
| Aclasta | Acide zolédronique | List with clinical criteria and/or conditions | Complete | July 20, 2011 | November 16, 2011 | |
| Aclasta | Acide zolédronique | Ostéoporose, femmes ménopausées | List with clinical criteria and/or conditions | Complete | November 29, 2007 | June 25, 2008 |
| Actemra | Tocilizumab | Arthrite juvénile idiopathique | List with clinical criteria and/or conditions | Complete | January 30, 2012 | July 19, 2012 |
| Actemra | Tocilizumab | Artérite à cellules géantes (ACG) | Reimburse with clinical criteria and/or conditions | Complete | September 25, 2017 | March 27, 2018 |
| Actemra | Tocilizumab | polyarthrite rhumatoïde | List with criteria/condition | Complete | March 3, 2014 | February 19, 2015 |
| Actemra | Tocilizumab | Arthrite juvénile idiopathique polyarticulaire | List with criteria/condition | Complete | July 29, 2013 | March 19, 2014 |
| Actemra | Tocilizumab | Polyarthrite rhumatoïde | List with clinical criteria and/or conditions | Complete | May 27, 2010 | November 17, 2010 |
| Actikerall | Fluorouracil et acide salicylique | kératose actinique hyperkératosique | Reimburse with clinical criteria and/or conditions | Complete | August 31, 2016 | March 22, 2017 |
| Adcirca | Tadalafil | Hypertension artérielle pulmonaire | List with clinical criteria and/or conditions | Complete | February 5, 2010 | July 15, 2010 |
| Adderall XR | Sels mixtes d’amphétamine | Trouble du déficit de l'attention avec hyperactivité | Do not list | Complete | April 13, 2004 | November 24, 2004 |
| Adderall XR | Sels mixtes d'amphétamine | Trouble du déficit de l'attention avec hyperactivité | Do not list | Complete | November 29, 2007 | June 25, 2008 |
| Adderall XR | Sels mixtes d'amphétamine | Trouble du déficit de l'attention avec hyperactivité | Withdrawn | December 15, 2004 | ||
| Adempas | Riociguat | Hypertension pulmonaire thromboembolique chronique | List with criteria/condition | Complete | September 30, 2013 | July 17, 2014 |
| Adempas | Riociguat | Hypertension artérielle pulmonaire (groupe 1 OMS) | List with criteria/condition | Complete | June 25, 2015 | December 17, 2015 |
| Adlyxine | lixisénatide | Diabète sucré de type 2 | Reimburse with clinical criteria and/or conditions | Complete | May 29, 2017 | November 23, 2017 |
| Admelog | Insuline lispro | Diabète sucré, type 1 et 2 | Cancelled | |||
| Advicor | Niacin/lovastatin | Hypercholestérolémie et dyslipidémie mixte | List | Complete | October 18, 2005 | April 26, 2006 |
| Aermony RespiClick | propionate de fluticasone | L’asthme | Reimburse with clinical criteria and/or conditions | Complete | October 4, 2017 | December 19, 2018 |
| Afinitor | Évérolimus | Astrocytome sous-épendymaire à cellules géantes associé à la sclérose tubéreuse de Bourneville | Do not list | Complete | March 19, 2014 | April 15, 2015 |
| Afinitor | Évérolimus | Angiomyolipome rénal avec sclérose tubéreuse de Bourneville | Do not list | Complete | March 8, 2013 | September 25, 2013 |
| Aimovig | érénumab | Migraine | Reimburse with clinical criteria and/or conditions | Complete | May 2, 2019 | July 22, 2020 |
| Ajovy | frémanézumab | La migraine | Active | June 3, 2020 | ||
| Akynzeo | nétupitant / palonosétron | Prévention des nausées et vomissements associés à la chimiothérapie | Reimburse with clinical criteria and/or conditions | Complete | December 8, 2017 | June 20, 2018 |
| Aldurazyme | Laronidase | Mucopolysaccharidose 1, maladie de Hurler, maladie de Hurler-Scheie, maladie de Scheie | Do not list | Complete | February 3, 2005 | July 14, 2005 |
| Aloxi (injection) | Chlorhydrate de palonosétron | Prévention des nausées et vomissements induits par la chimiothérapie | Do not list at the submitted price | Complete | October 5, 2012 | May 15, 2013 |
| Aloxi (capsule) | Chlorhydrate de palonosétron | Prévention des nausées et vomissements induits par la chimiothérapie | Do not list | Complete | October 5, 2012 | April 24, 2013 |
| Aloxi (capsule) | Palonosetron | Prévention des nausées et vomissements induits par la chimiothérapie | Withdrawn | February 6, 2015 | ||
| Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | Cancelled | October 26, 2006 | ||
| Altace Plus Felodipine | Ramipril/félodipine à libération prolongée | Hypertension | Do not list | Complete | June 22, 2006 | November 15, 2006 |
| Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | List | Complete | March 26, 2007 | June 14, 2007 |
| Alvesco | Ciclesonide | Asthme | List | Complete | July 24, 2006 | December 20, 2006 |
| Amevive | Aléfacept | Psoriasis en plaques de modéré à grave | Do not list | Complete | February 28, 2006 | September 27, 2006 |
| Amevive | Aléfacept | Psoriasis en plaques de modéré à grave | Do not list | Complete | November 16, 2004 | May 26, 2005 |
| Vocabria and Cabenuva | cabotégravir sodium cabotégravir-rilpivirine | Infection par VIH-1 | Reimburse with clinical criteria and/or conditions | Complete | August 19, 2019 | July 22, 2020 |
| Anoro Ellipta | Uméclidinium et vilantérol | Maladie pulmonaire obstructive chronique | List with criteria/condition | Complete | February 26, 2014 | January 15, 2015 |
| Apidra | Insuline glulisine | Diabète de type 1 et de type 2 | List in a similar manner to other drugs in class | Complete | August 29, 2008 | February 19, 2009 |
| Apprilon | Doxycycline monohydratée | Rosacée | Do not list | Complete | April 27, 2012 | March 27, 2013 |
| Aptiom | Acétate d'eslicarbazépine | Épilepsie, crises partielles | List with criteria/condition | Complete | August 15, 2014 | April 16, 2015 |
| Aptivus | Tipranavir | Infection par le VIH | List with clinical criteria and/or conditions | Complete | December 15, 2005 | May 17, 2006 |
| Arbesda RespiClick | Propionate de fluticasone / xinafoate de salmétérol | Asthme | Reimburse with clinical criteria and/or conditions | Complete | October 4, 2017 | December 19, 2018 |
| Arnuity Ellipta | Furoate de fluticasone | Asthme | List with criteria/condition | Complete | June 26, 2015 | December 17, 2015 |
| ASMANEX | Furoate de mométasone | Prophylaxie (bronchique) de l'asthme sensible aux stéroïdes | List | Complete | November 10, 2011 | May 16, 2012 |
| Atectura Breezhaler | indacatérol et furoate de mométasone | Le traitement d’entretien de l’asthme chez l’adulte et l’adolescent de 12 ans ou plus | Active | May 19, 2020 | ||
| Atripla | Éfavirenz, emtricitabine, fumarate de ténofovir disoproxil | VIH | List with clinical criteria and/or conditions | Complete | October 30, 2007 | April 17, 2008 |
| Aubagio | Teriflunomide | Sclérose en plaques cyclique | Do not list at the submitted price | Complete | August 28, 2013 | June 18, 2014 |
| Somatuline Autogel | Acétate de lanréotide | Acromégalie | List in a similar manner to other drugs in class | Complete | February 20, 2007 | July 19, 2007 |
| Avodart | Dutastéride | Hyperplasie bénigne de la prostate | List in a similar manner to other drugs in class | Complete | August 24, 2004 | January 20, 2005 |
| Axert | Almotriptan | Migraine | List in a similar manner to other drugs in class | Complete | December 24, 2003 | May 27, 2004 |
| Azarga | Suspension de brinzolamide et de maléate de timolol | Glaucome et hypertension oculaire | List in a similar manner to other drugs in class | Complete | August 28, 2009 | February 18, 2010 |
| Azilect | Mésylate de rasagiline | Maladie de Parkinson | Do not list | Complete | September 1, 2006 | March 28, 2007 |
| Azilect | Mésylate de rasagiline | Maladie de Parkinson | Complete | March 10, 2009 | ||
| Zenhale (aérosol pour inhalation) | Furoate de mométasone et formotérol | Traitement d'entretien de l'asthme (adultes et enfants de 12 ans ou plus) | Do not list | Complete | February 16, 2011 | September 28, 2011 |
| Banzel | Rufinamide | Syndrome de Lennox-Gastaut; traitement d'appoint des convulsions | List with clinical criteria and/or conditions | Complete | September 20, 2011 | March 15, 2012 |
| Baqsimi | Glucagon | Réactions hypoglycémiques graves | Reimburse with clinical criteria and/or conditions | Complete | July 24, 2019 | January 22, 2020 |
| Baraclude | Entécavir | Hépatite B (chronique) | List with clinical criteria and/or conditions | Complete | December 12, 2006 | November 28, 2007 |
| Basaglar | Insuline glargine | diabète de type 1 ou 2 | List with clinical criteria and/or conditions | Active | October 5, 2015 | April 14, 2016 |
| Benlysta | Bélimumab | lupus érythémateux systémique | Do not reimburse | Complete | May 29, 2019 | April 22, 2020 |
| Benlysta | Bélimumab | Lupus érythémateux disséminé | Do not list | Complete | September 19, 2011 | April 25, 2012 |
| Beovu | brolucizumab | Dégénérescence maculaire liée à l'âge | Reimburse with clinical criteria and/or conditions | Complete | September 26, 2019 | May 21, 2020 |
| Biktarvy | Bictégravir/emtricitabine/ténofovir/alafénamide | Infection au VIH-1 | Reimburse with clinical criteria and/or conditions | Complete | April 30, 2018 | October 25, 2018 |
| Inflectra (Produit biologique ultérieur) | Infliximab | Maladie de Crohn et colite ulcéreuse | Reimburse with clinical criteria and/or conditions | Complete | April 12, 2016 | October 25, 2016 |
| Botox | Toxine botulinique de type A | Migraines chroniques | Do not list | Complete | August 15, 2013 | May 28, 2014 |
| Botox | Toxine botulinique de type A | Incontinence urinaire | List with criteria/condition | Complete | November 25, 2013 | November 12, 2014 |
| Botox | Toxine botulinique de type A | Hyperactivité neurogène du détrusor | List with clinical criteria and/or conditions | Complete | January 31, 2012 | July 19, 2012 |
| Botox | onabotulinumtoxinA | migraine chronique | Reimburse with clinical criteria and/or conditions | Complete | November 2, 2018 | October 17, 2019 |
| Enerzair Breezhaler | indacatérol, glycopyrronium et furoate de momatésone | Le traitement d’entretien de l’asthme chez l’adulte | Active | May 19, 2020 | ||
| Ultibro Breezhaler | Indacatérol/glycopyrronium | MPOC | List with criteria/condition | Complete | February 3, 2014 | December 19, 2014 |
| Brenzys | Étanercept | Polyarthrite rhumatoïde, spondylarthrite ankylosante | Reimburse with clinical criteria and/or conditions | Complete | April 20, 2016 | October 25, 2016 |
| Breo Ellipta | furoate de fluticasone et vilantérol | Asthme | Withdrawn | May 2, 2018 | ||
| Breo Ellipta | Furoate de fluticasone et vilantérol | Maladie pulmonaire obstructive chronique (MPOC) | List with criteria/condition | Complete | October 29, 2013 | August 18, 2014 |
| Breo Ellipta | fluticasone furoate/vilantérol | MPOC | Withdrawn | June 28, 2017 | ||
| Breo Ellipta | Furoate de fluticasone et vilantérol (sous forme de trifénatate) | Asthme | List with clinical criteria and/or conditions | Complete | August 10, 2015 | February 18, 2016 |
| Brilinta | Ticagrélor | Syndrome coronarien aigu (SCA) | Cancelled | June 8, 2010 | ||
| Brilinta | Ticagrélor | Prévention des incidents thrombotiques en contexte de syndrome coronarien aigu | Do not list | Complete | June 1, 2011 | December 16, 2011 |
| Brilinta | ticagrélor | Prévention des événements athérothrombotiques avec antécédents d’infarctus du myocarde | Reimburse with clinical criteria and/or conditions | Complete | February 18, 2016 | August 25, 2016 |
| Brineura | cerliponase alpha | Lipofuscinoses ceroïdes neuronales de type 2 | Reimburse with clinical criteria and/or conditions | Complete | July 31, 2018 | May 23, 2019 |
| Brivlera | Brivaracétam | Epilepsie, crises partielles | Complete | April 19, 2016 | ||
| BuTrans | Timbre transdermique de buprénorphine | Douleur persistante (intensité modérée) | Do not list | Complete | May 9, 2011 | September 28, 2011 |
| BuTrans | Timbre transdermique de buprénorphine | Douleur persistante (intensité modérée) | Cancelled | October 15, 2010 | ||
| Byetta | Exénatide | Diabète de type 2 | Do not list | Complete | August 23, 2011 | July 19, 2012 |
| Bystolic | Nébivolol | Hypertension artérielle essentielle | Do not list at the submitted price | Complete | February 4, 2013 | July 18, 2013 |
| Cablivi | caplacizumab | Purpura thrombocytopénique thrombotique acquis | Do not reimburse | Complete | September 13, 2019 | August 26, 2020 |
| Caduet | Bésylate d’amlodipine et atorvastatine calcique | Hypertension et dyslipidémie | List with clinical criteria and/or conditions | Complete | December 15, 2005 | May 17, 2006 |
| Campral | Acamprosate calcique | Maintien de l'abstinence d'alcool | Complete | July 22, 2008 | ||
| Campral | Acamprosate calcique | Maintien de l'abstinence d'alcool | List with clinical criteria and/or conditions | Complete | August 29, 2007 | March 27, 2008 |
| Cayston | Solution d'aztréonam pour inhalation | Infection pulmonaire chronique à Pseudomonas aeruginosa chez le patient atteint de fibrose kystique | List with clinical criteria and/or conditions | Complete | December 2, 2010 | July 18, 2011 |
| Celsentri | Maraviroc | VIH | List with clinical criteria and/or conditions | Complete | May 7, 2008 | November 12, 2008 |
| Celsentri | Maraviroc | VIH | Withdrawn | November 2, 2007 | ||
| Celsentri | Maraviroc | Infection au VIH-2 chez l'adulte jamais encore traité | Do not list | Complete | December 8, 2010 | July 18, 2011 |
| Cerdelga | Éliglustat | Maladie de Gaucher | Reimburse with clinical criteria and/or conditions | Complete | January 20, 2017 | July 26, 2017 |
| Champix | Tartrate de varénicline | Désaccoutumance au tabac | List with clinical criteria and/or conditions | Complete | March 21, 2007 | August 16, 2007 |
| Cimzia | Certolizumab pegol | Polyarthrite rhumatoïde | Do not list | Complete | September 3, 2009 | May 27, 2010 |
| Cimzia | certolizumab pégol | Psoriasis en plaques, de modéré à grave | Reimburse with clinical criteria and/or conditions | Complete | May 13, 2019 | November 20, 2019 |
| Cimzia | Certolizumab pegol | spondylarthrite ankylosante | List with criteria/condition | Complete | June 23, 2014 | April 17, 2015 |
| Cimzia | Certolizumab pegol | Arthrite psoriasique | List with criteria/condition | Complete | September 2, 2014 | April 17, 2015 |
| Cinqair | reslizumab | L'asthme éosinophile | Reimburse with clinical criteria and/or conditions | Complete | October 24, 2018 | March 27, 2019 |
| Cinqair | Reslizumab | Asthme à éosinophiles | Reimburse with clinical criteria and/or conditions | Complete | August 4, 2016 | March 22, 2017 |
| Cipralex | Oxalate d'escitalopram | Dépression, trouble dépressif majeur (TDM) | Withdrawn | August 3, 2005 | ||
| Cipralex | Oxalate d'escitalopram | Dépression, trouble dépressif majeur (TDM) | Do not list | Complete | June 8, 2006 | January 24, 2007 |
| Ciprodex | Suspension otique de ciprofloxacine et de dexaméthasone | Otite moyenne avec otorrée et otite externe aigüe | Do not list | Complete | June 11, 2004 | January 26, 2005 |
| Ciprodex | Suspension otique de ciprofloxacine et de dexaméthasone | Otite moyenne avec otorrée et otite externe aigüe | List with clinical criteria and/or conditions | Complete | June 15, 2007 | October 18, 2007 |
| Combigan Ophthalmic Solution | Tartrate de brimonidine et maléate de timolol | Glaucome | List with clinical criteria and/or conditions | Complete | December 15, 2003 | May 27, 2004 |
| COMPLERA | Emtricitabine/rilpivirine/fumarate de ténofovir disoproxil | Infection au VIH-1 chez l'adulte n'ayant jamais subi de traitement antirétroviral | List | Complete | October 19, 2011 | April 19, 2012 |
| À confirmer | propionate d’halobétasol et tazarotène | Psoriasis en plaques de modéré à grave | Withdrawn | February 4, 2019 | ||
| À confirmer | filgrastim | Prévention ou le traitement de la neutropénie dans différentes indications | Cancelled | November 1, 2018 | ||
| À confirmer | Darunavir / cobicistat | infection par le VIH | Withdrawn | April 4, 2014 | ||
| À confirmer | Ravulizumab | Hémoglobinurie paroxystique nocturne | Suspended | July 4, 2019 | ||
| À confirmer | filgrastim | Neutropénie, mobilisation des cellules sanguines (différentes indications) | Cancelled | |||
| À confirmer | Prévention de la grossesse | Withdrawn | September 26, 2019 | |||
| Constella | Linaclotide | Syndrome du colon irritable avec constipation | Do not list | Complete | December 17, 2014 | September 23, 2015 |
| Contrave | Chlorhydrate de naltrexone et chlorhydrate de bupropion | Prise en charge du surpoids chronique chez l’adulte | Do not reimburse | Complete | May 1, 2019 | May 27, 2020 |
| Copaxone | Acétate de glatiramère | Syndrome clinique isolé, caractéristique de la sclérose en plaques | Do not list | Complete | April 29, 2009 | November 25, 2009 |
| Cortiment | Budésonide | Colite ulcéreuse | Do not reimburse | Complete | May 24, 2016 | March 22, 2017 |
| Cosentyx | Sécukinumab | Arthrite psoriasique | Reimburse with clinical criteria and/or conditions | Complete | February 19, 2016 | August 23, 2016 |
| Cosentyx | Sécukinumab | Psoriasis en plaques modéré à grave | List with clinical criteria and/or conditions | Complete | December 8, 2014 | October 28, 2015 |
| Cosentyx | Sécukinumab | Spondylarthrite ankylosante | Reimburse with clinical criteria and/or conditions | Complete | February 19, 2016 | August 23, 2016 |
| Nucynta CR | Tapentadol | Douleur d’intensité modérée à modérément grave | Do not list | Complete | February 1, 2011 | September 28, 2011 |
| Cresemba | Isavuconazole | Traitement de l'aspergillose et de la mucormycose invasives | Reimburse with clinical criteria and/or conditions | Complete | November 2, 2018 | May 15, 2019 |
| Crysvita | Burosumab | Traitement de l’hypophosphatémie liée à l’X | Reimburse with clinical criteria and/or conditions | Complete | July 23, 2019 | May 27, 2020 |
| Cubicin | Daptomycin | Infections de la peau et des structures cutanées et bactériémie | Do not list | Complete | March 6, 2008 | September 24, 2008 |
| Cuvposa | Glycopyrrolate | Sialorrhée chronique grave, neurologique | Do not reimburse | Complete | May 31, 2019 | June 24, 2020 |
| Cymbalta | Duloxetine hydrochloride | Pain, Neuropathic, Diabetic | List with clinical criteria and/or conditions | Complete | February 8, 2008 | August 14, 2008 |
| Cymbalta | Chlorhydrate de duloxétine | Trouble dépressif majeur (TDM) | Do not list | Complete | February 8, 2008 | August 14, 2008 |
| Cystadrops | Cystéamine | Dépôts cornéens de cristaux de cystine | Reimburse with clinical criteria and/or conditions | Complete | December 10, 2018 | June 18, 2019 |
| Daklinza | Daclatasvir | Hépatite C chronique | List with clinical criteria and/or conditions | Complete | February 13, 2015 | September 21, 2015 |
| Daklinza | Daclatasvir | Hépatite C chronique | Reimburse with clinical criteria and/or conditions | Complete | January 6, 2016 | May 19, 2016 |
| Daxas | Roflumilast | Maladie pulmonaire obstructive chronique (MPOC) | Do not list | Complete | November 30, 2010 | July 27, 2011 |
| Delstrigo | doravirine, lamuvidine et fumarate de ténofovir disoproxil | infection par le VIH-1 | Reimburse with clinical criteria and/or conditions | Complete | November 16, 2018 | May 14, 2019 |
| Denavir | Penciclovir | Herpès labial (feu sauvage) | Do not list | Complete | September 20, 2006 | April 26, 2007 |
| Descovy | Emtricitabine /ténofovir alafénamide | Infection par le VIH-1 | Reimburse with clinical criteria and/or conditions | Complete | January 29, 2016 | August 24, 2016 |
| Diacomit | Stiripentol | Syndrome de Dravet | List with criteria/condition | Complete | October 30, 2013 | October 16, 2014 |
| Dificid | Fidaxomicine | Infection à Clostridium difficile | Do not list at the submitted price | Complete | July 10, 2012 | December 19, 2012 |
| Dovato | dolutégravir/lamivudine | Infection par le VIH-1 | Reimburse with clinical criteria and/or conditions | Complete | February 21, 2019 | September 30, 2019 |
| Duaklir Genuair | Bromure d’aclidinium et fumarate de formotérol dihydraté | Maladie pulmonaire obstructive chronique (MPOC) | List with clinical criteria and/or conditions | Complete | April 1, 2015 | September 18, 2015 |
| Duobrii | Propionate d'halobétasol et tazarotène | Psoriasis en plaques, modéré à grave | Active | January 24, 2020 | ||
| Duodopa | Levodopa / carbidopa | Maladie de Parkinson | Do not list | Complete | December 19, 2008 | July 22, 2009 |
| Duodopa | lévodopa/carbidopa (demande de régimes d'assurance médicaments) | Maladie de Parkinson | Reimburse with clinical criteria and/or conditions | Complete | February 8, 2018 | August 22, 2018 |
| DuoTrav | Travoprost et maléate de timolol | Glaucome | List with clinical criteria and/or conditions | Complete | March 24, 2006 | August 24, 2006 |
| Dupixent | dupilumab | dermatite atopique | Do not reimburse | Complete | October 27, 2017 | June 27, 2018 |
| Dupixent | dupilumab | dermatite atopique | Reimburse with clinical criteria and/or conditions | Complete | October 22, 2019 | April 22, 2020 |
| Dupixent | dupilumab | Indiqué comme traitement d'entretien d'appoint de l'asthme modérée à grave avec inflammation de type 2 chez l'adulte et chez l'adolescent de 12 ans ou plus. Indiqué comme traitement d'entretien visant à améliorer la fonction pulmonaire. Indiqué comme traitement d'entretien de l'asthme chez le patient dépendant aux corticostéroïdes oraux, qu'il y ait ou non inflammation de type 2. | En attente | |||
| Dymista | Chlorhydrate d’azélastine et propionate de fluticasone | Rhinite saisonnière | Do not list | Complete | December 9, 2014 | June 17, 2015 |
| Dysport Therapeutic | abobotulinumtoxinA | Dystonie cervicale | Reimburse with clinical criteria and/or conditions | Complete | January 31, 2017 | July 26, 2017 |
| Dysport Therapeutic | abobotulinumtoxinA | spasticité des membres inférieurs | Reimburse with clinical criteria and/or conditions | Complete | February 7, 2018 | August 21, 2018 |
| Dysport Therapeutic | abobotulinumtoxinA | Spasticité des membres supérieurs | Reimburse with clinical criteria and/or conditions | Complete | April 24, 2017 | October 24, 2017 |
| Ebixa | Chlorhydrate de mémantine | Démence (type Alzheimer) modérée à grave | Do not list | Complete | December 21, 2004 | November 23, 2005 |
| Edarbi | Azilsartan médoxomil | Hypertension artérielle essentielle | Do not list at the submitted price | Complete | March 8, 2013 | October 17, 2013 |
| Edarbyclor | Azilsartan médoxomil et chlortalidone | Hypertension artérielle essentielle | Do not list | Complete | March 8, 2013 | October 17, 2013 |
| Edurant | Rilpivirine | Infection par le HIV (traitement; adulte jamais traité) | List | Complete | July 29, 2011 | February 15, 2012 |
| Effient | Prasugrel | Syndrome coronarien aigu (SCA) | Do not list | Complete | December 12, 2011 | June 14, 2012 |
| Effient | Chlorhydrate de prasugrel | Syndrome coronarien aigu (SCA) | Do not list | Complete | May 5, 2010 | February 16, 2011 |
| Egrifta | Tésamoréline | Lipodystrophie associée à l’infection par le VIH | Do not reimburse | Complete | March 2, 2016 | August 24, 2016 |
| Elaprase | Idursulfase | mucopolysaccharidose type II, maladie de Hunter | Do not list | Complete | July 13, 2007 | December 19, 2007 |
| Elelyso | Taliglucérase alfa | Maladie de Gaucher | Do not list | Complete | August 15, 2014 | October 28, 2015 |
| Eliquis | Apixaban | Prévention des incidents thromboemboliques veineux | List with clinical criteria and/or conditions | Complete | December 20, 2011 | June 14, 2012 |
| Eliquis | Apixaban | Prévention des incidents thromboemboliques (fibrillation auriculaire) | List with clinical criteria and/or conditions | Complete | September 25, 2012 | March 20, 2013 |
| Eliquis | Apixaban | Traitement et prévention de la récurrence de l’incident thromboembolique veineux | List with clinical criteria and/or conditions | Complete | September 18, 2014 | May 7, 2015 |
| Trelegy Ellipta | furoate de fluticasone uméclidinium vilantérol | maladie pulmonaire obstructive chronique (MPOC) | Reimburse with clinical criteria and/or conditions | Complete | March 1, 2018 | August 23, 2018 |
| Incruse Ellipta | Uméclidinium | Maladie pulmonaire obstructive chronique (MPOC) | List | Complete | March 4, 2015 | September 18, 2015 |
| Emend | Aprépitant | Nausées et vomissements causés par la chimiothérapie | List with clinical criteria and/or conditions | Complete | August 29, 2007 | February 20, 2008 |
| Enablex | Bromhydrate de darifénacine | Vessie hyperactive | Do not list | Complete | April 26, 2006 | October 19, 2006 |
| Enablex | Bromhydrate de darifénacine | Vessie hyperactive | List with clinical criteria and/or conditions | Complete | October 1, 2008 | April 16, 2009 |
| Enspryng | satralizumab | trouble du spectre de la neuromyélite optique | En attente | |||
| Entresto | Sacubitril/valsartan | Insuffisance cardiaque, classe NYHA II ou III | List with clinical criteria and/or conditions | Complete | September 18, 2015 | March 18, 2016 |
| Entresto | sacubritil/valsartan | Insuffisance cardiaque, classe NYHA II ou III | Active | May 22, 2020 | ||
| Entyvio | védolizumab | Colite ulcéreuse | Reimburse with clinical criteria and/or conditions | Complete | November 21, 2019 | May 19, 2020 |
| Entyvio | Védolizumab | Colite ulcéreuse | List with clinical criteria and/or conditions | Complete | February 20, 2015 | October 28, 2015 |
| Entyvio | vedolizumab | maladie de Crohn | Active | July 23, 2020 | ||
| Entyvio | Védolizumab | Maladie de Chrohn | Reimburse with clinical criteria and/or conditions | Complete | April 27, 2016 | October 27, 2016 |
| Epclusa | Sofosbuvir/velpatasvir | Hépatite C chronique | Reimburse with clinical criteria and/or conditions | Complete | April 22, 2016 | October 26, 2016 |
| Erelzi | étanercept | Spondylarthrite ankylosante, polyarthrite juvénile idiopathique, polyarthrite rhumatoïde | Reimburse with clinical criteria and/or conditions | Complete | February 2, 2017 | July 25, 2017 |
| Esbriet | Pirfénidone | Fibrose pulmonaire idiopathique, de légère à modérée | List with criteria/condition | Complete | August 29, 2014 | April 15, 2015 |
| Esbriet | Pirfénidone | Fibrose pulmonaire idiopathique, de légère à modérée | Do not list | Complete | October 5, 2012 | April 18, 2013 |
| Eucrisa | crisaborole | dermatite atopique | Do not reimburse | Complete | May 25, 2018 | March 27, 2019 |
| Evra | Norgelestromine et éthinylestradiol | Timbre contraceptif | Do not list | Complete | December 19, 2003 | June 23, 2004 |
| Exelon Patch | Rivastigmine | Démence (type Alzheimer) | Do not list | Complete | December 21, 2007 | July 23, 2008 |
| Exjade | Déférasirox | Hémochromatose | List with clinical criteria and/or conditions | Complete | October 26, 2006 | April 19, 2007 |
| Eylea | Aflibercept | Dégénérescence maculaire liée à l'âge | List with criteria/condition | Complete | November 18, 2013 | October 20, 2014 |
| Eylea | Aflibercept | Œdème maculaire secondaire à une occlusion veineuse rétinienne | Reimburse with clinical criteria and/or conditions | Complete | December 14, 2015 | July 27, 2016 |
| Eylea | Aflibercept | œdème maculaire diabétique | List with clinical criteria and/or conditions | Complete | September 16, 2014 | May 7, 2015 |
| Eylea | Aflibercept | œdème maculaire secondaire à une occlusion de la veine centrale de la rétine | List with clinical criteria and/or conditions | Complete | October 17, 2014 | May 7, 2015 |
| Fabrazyme | Agalsidase bêta | Maladie de Fabry | Do not list | Complete | December 10, 2004 | May 18, 2005 |
| Fabrazyme | Agalsidase bêta | Maladie de Fabry | Do not list | Complete | February 24, 2004 | November 24, 2004 |
| Fampyra | Fampridine | Sclérose en plaques, amélioration de la capacité de marche | Withdrawn | November 6, 2014 | ||
| Fampyra | Fampridine | Sclérose en plaques, amélioration de la capacité de marche | Do not list | Complete | April 16, 2012 | November 28, 2012 |
| Fasenra | benralizumab | Asthme grave, éosinophile | Reimburse with clinical criteria and/or conditions | Complete | October 24, 2018 | March 27, 2019 |
| Fasenra | benralizumab | Asthme grave, éosinophile | Reimburse with clinical criteria and/or conditions | Complete | February 23, 2018 | August 23, 2018 |
| Fentora | Fentanyl buccal | Accès douloureux transitoires, adultes cancéreux | Do not reimburse | Complete | July 12, 2016 | February 21, 2017 |
| Ferriprox | Défériprone | Surcharge en fer transfusionnelle | List with clinical criteria and/or conditions | Complete | September 24, 2015 | March 18, 2016 |
| Fibristal | Acétate d’ulipristal | Fibromes utérins (signes et symptômes) | List with criteria/condition | Complete | April 17, 2013 | November 15, 2013 |
| Fibristal | acétate d’ulipristal | le traitement des fibromes utérins (signes et symptômes) | Reimburse with clinical criteria and/or conditions | Complete | June 21, 2017 | November 22, 2017 |
| Fibristal | Acétate d'ulipristal | Fibromes utérins (signes et symptômes) | Reimburse with clinical criteria and/or conditions | Complete | March 28, 2019 | July 24, 2019 |
| Finacea | Acide azélaïque | Rosacée | List | Complete | August 31, 2010 | February 16, 2011 |
| Firazyr | Icatibant | angioedème héréditaire | List with clinical criteria and/or conditions | Complete | March 4, 2014 | December 19, 2014 |
| Firazyr | icatibant | La prise en charge des crises aigües d’angiœdème héréditaire chez l’enfant, l’adolescent ou l’enfant de deux ans et plus présentant un déficit en inhibiteur de la C1-estérase | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | NotFiled | ||
| Forteo | Tériparatide injectable (source ADNr) | Ostéoporose | Withdrawn | December 18, 2008 | ||
| Forteo | Tériparatide injectable (source ADNr) | Ostéoporose grave (chez la femme) | Do not list | Complete | October 23, 2009 | March 17, 2010 |
| Forteo | Tériparatide injectable (source ADNr) | Ostéoporose induite par les glucocorticoïdes | Do not list | Complete | December 18, 2008 | July 22, 2009 |
| Forteo | Tériparatide injectable (source ADNr) | Ostéoporose | Withdrawn | May 29, 2006 | ||
| Forteo | Tériparatide injectable (source ADNr) | Ostéoporose | Withdrawn | June 12, 2009 | ||
| Forteo | Tériparatide injectable (source ADNr) | Ostéoporose | Do not list | Complete | June 8, 2004 | December 22, 2004 |
| Forxiga | Dapagliflozin | Diabète sucré (Type 2) | List with clinical criteria and/or conditions | Complete | April 30, 2015 | November 20, 2015 |
| Forxiga | dapagliflozine | diabète de type 2 | Do not list | Complete | September 4, 2015 | April 27, 2016 |
| Forxiga | dapagliflozine | L’insuffisance cardiaque à fraction d’éjection réduite | Active | March 31, 2020 | ||
| Fosavance | Alendronate monosodique et cholécalciférol | Ostéoporose | Do not list | Complete | March 27, 2006 | September 27, 2006 |
| Fosrenol | Carbonate de lanthane hydraté | Hyperphosphatémie, insuffisance rénale terminale | Do not list | Complete | June 28, 2007 | January 30, 2008 |
| Fulphila | pegfilgrastim | Neutropénie fébrile associée à un cancer non myéloïde | Complete | November 14, 2018 | ||
| Fycompa | Pérampanel | Épilepsie, crise tonico-clonique généralisée | Reimburse with clinical criteria and/or conditions | Complete | November 24, 2015 | May 18, 2016 |
| Fycompa | Pérampanel | Épilepsie, crises partielles | List with criteria/condition | Complete | March 8, 2013 | October 17, 2013 |
| Galafold | migalastat | Maladie de Fabry | Reimburse with clinical criteria and/or conditions | Complete | June 9, 2017 | January 24, 2018 |
| Galexos | Siméprévir | Hépatite C chronique | List with criteria/condition | Complete | August 22, 2013 | June 18, 2014 |
| Gelnique | gel de chlorure d’oxybutynine | Vessie hyperactive | Do not list | Complete | October 25, 2011 | May 24, 2012 |
| Genotropin | Somatropine | Syndrome de Turner | List with criteria/condition | Complete | May 27, 2013 | December 20, 2013 |
| Genotropin | Somatropine | Carence en hormone de croissance chez l'adulte | List with criteria/condition | Complete | May 27, 2013 | December 20, 2013 |
| Genotropin | Somatropine | Carence en hormone de croissance chez l'enfant | List with criteria/condition | Complete | May 27, 2013 | December 20, 2013 |
| Tudorza Genuair | Bromure d’aclidinium | Maladie pulmonaire obstructive chronique (MPOC) | List with criteria/condition | Complete | August 21, 2013 | April 21, 2014 |
| Genvoya | Elvitégravir/cobicistat/emtricitabine/ténofovir alafénamide | Infection au VIH | List | Complete | September 24, 2015 | March 18, 2016 |
| Gilenya | Fingolimod | Sclérose en plaques | List with clinical criteria and/or conditions | Complete | May 10, 2011 | November 16, 2011 |
| Glatect | Acétate de glatiramer | Sclérose en plaques cyclique | Reimburse with clinical criteria and/or conditions | Complete | January 20, 2017 | July 25, 2017 |
| Grastek | Fléole des prés | Allergie (graminées) | Do not list | Complete | September 30, 2013 | September 24, 2014 |
| Grastofil | Filgrastim | Prévention ou traitement de la neutropénie sous diverses indications | List with clinical criteria and/or conditions | Complete | September 11, 2015 | March 18, 2016 |
| Harvoni | Lédipasvir/sofosbuvir | Hépatite C chronique | List with criteria/condition | Complete | September 15, 2014 | March 18, 2015 |
| Harvoni | lédipasvir, sofosbuvir | Hépatite C, chronique | Reimburse with clinical criteria and/or conditions | Complete | January 6, 2016 | May 18, 2016 |
| Hemangiol | Propranolol | Hémangiome infantile | Withdrawn | December 23, 2014 | ||
| Hemangiol | Solution orale de propranolol | Hémangiome infantile | Reimburse with clinical criteria and/or conditions | Complete | August 25, 2016 | February 21, 2017 |
| Hemlibra | émicizumab | prévention de l'hémorragie, hémophilie A | Active | June 30, 2020 | ||
| Hepsera | Adéfovir dipivoxil | Hépatite B | List with clinical criteria and/or conditions | Complete | June 29, 2007 | October 18, 2007 |
| Hepsera | Adéfovir dipivoxil | Hépatite B | Do not list | Complete | April 24, 2006 | November 29, 2006 |
| Holkira Pak | ombitasvir/paritaprévir/ritonavir et dasabuvir | Hépatite C, chronique | Reimburse with clinical criteria and/or conditions | Complete | January 6, 2016 | May 26, 2016 |
| Holkira Pak | Ombitasvir/paritaprévir/ritonavir and dasabuvir | Hépathite C chronique | List with clinical criteria and/or conditions | Complete | December 3, 2014 | June 18, 2015 |
| Humira | Adalimumab | Hidrosadénite suppurée | Reimburse with clinical criteria and/or conditions | Complete | November 3, 2015 | May 19, 2016 |
| Humira | Adalimumab | Spondylarthrite ankylosante | List with clinical criteria and/or conditions | Complete | November 17, 2006 | June 27, 2007 |
| Humira | Adalimumab | Maladie de Crohn | List with clinical criteria and/or conditions | Complete | July 12, 2007 | December 19, 2007 |
| Humira | Adalimumab | Polyarthrite rhumatoïde | List with clinical criteria and/or conditions | Complete | September 24, 2004 | February 11, 2005 |
| Humira | Adalimumab | Arthrite juvénile idiopathique | List with clinical criteria and/or conditions | Complete | February 4, 2013 | July 18, 2013 |
| Humira | Adalimumab | Psoriasis | List with clinical criteria and/or conditions | Complete | April 15, 2008 | October 16, 2008 |
| Humira | Adalimumab | Arthrite psoriasique | List with clinical criteria and/or conditions | Complete | June 21, 2006 | November 29, 2006 |
| Humira | Adalimumab | Colite ulcéreuse | Do not list at the submitted price | Complete | September 25, 2015 | April 15, 2016 |
| Humira | Adalimumab | Colite ulcéreuse | Withdrawn | December 23, 2013 | ||
| Simponi I.V. | Golimumab | Polyarthrite rhumatoïde | List with criteria/condition | Complete | September 12, 2013 | July 17, 2014 |
| Stelara/Stelara I.V. | ustekinumab | Maladie de Crohn | Reimburse with clinical criteria and/or conditions | Complete | September 12, 2016 | March 21, 2017 |
| Stelara/Stelara I.V | ustékinumab | Colite ulcéreuse | Reimburse with clinical criteria and/or conditions | Complete | August 12, 2019 | July 16, 2020 |
| Ikervis | cyclosporine | Kératite sévère | Withdrawn | May 15, 2017 | ||
| Ilaris | Canakinumab | Syndrome périodique associé à la cryopyrine | Do not list | Complete | July 7, 2010 | January 26, 2011 |
| Ilaris | Canakinumab | Arthrite idiopathique juvénile systémique | Reimburse with clinical criteria and/or conditions | Complete | December 23, 2015 | June 17, 2016 |
| Ilumya | Tildrakizumab | Psoriasis en plaque, modéré à grave | Suspended | July 15, 2019 | ||
| Iluvien | implant intravitréen d'acétonide de fluocinolone | œdème maculaire diabétique | Do not reimburse | Complete | April 3, 2019 | September 26, 2019 |
| Iluvien | fluocinolone acétonide | œdème maculaire diabétique | Withdrawn | December 21, 2017 | ||
| Imbruvica | ibrutinib | Réaction chronique du greffon contre l’hôte | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | NotFiled | ||
| Incivek | Télaprévir | Infection à l'hépatite C (génotype 1), chronique | List with clinical criteria and/or conditions | Complete | August 23, 2011 | February 15, 2012 |
| Incivek | Télaprévir | Hépatite C chronique | List with criteria/condition | Complete | December 21, 2012 | June 13, 2013 |
| Incivek | Télaprévir | Hépatite C chronique | List with criteria/condition | Complete | February 19, 2013 | June 13, 2013 |
| Inflectra | Infliximab | Spondylarthrite ankylosante, psoriasis en plaques, arthrite psoriasique, polyarthrite rhumatoïde | List with criteria/condition | Complete | June 17, 2014 | December 19, 2014 |
| Inspiolto Respimat | Tiotropium / olodatérol | Maladie pulmonaire obstructive chronique (MPOC) (COPD) | List with criteria/condition | Complete | June 4, 2015 | December 17, 2015 |
| Inspra | Éplérénone | Après un infarctus du myocarde | Do not list | Complete | May 6, 2009 | November 25, 2009 |
| Inspra | Éplérénone | Insuffisance cardiaque, classe II de la NYHA | Do not list at the submitted price | Complete | July 12, 2013 | April 24, 2014 |
| Intelence | Étravirine | VIH | List with clinical criteria and/or conditions | Complete | April 2, 2008 | August 14, 2008 |
| Intuniv XR | Chlorhydrate de guanfacine | Trouble d'hyperactivité avec déficit de l'attention | Do not list | Complete | August 27, 2013 | September 24, 2014 |
| Invega | Palipéridone | Schizophrénie | Do not list | Complete | November 1, 2007 | May 28, 2008 |
| Invega Sustenna | Palmitate de palipéridone | Schizophrénie | Do not list | Complete | July 9, 2010 | April 25, 2011 |
| Invokamet | Canagliflozine et metformine | Diabète de type 2 | Reimburse with clinical criteria and/or conditions | Complete | March 3, 2016 | August 25, 2016 |
| Invokana | Canagliflozine | Diabète de type 2 | Withdrawn | June 5, 2013 | ||
| Invokana | Canagliflozine | Diabète de type 2 | List with criteria/condition | Complete | February 24, 2014 | January 15, 2015 |
| Iressa | Géfitinib | Cancer du poumon non à petites cellules | Do not list | Complete | December 22, 2003 | June 23, 2004 |
| Isentress | Raltégravir | VIH (patients jamais traités) | Do not list | Complete | December 4, 2009 | June 23, 2010 |
| Isentress | Raltégravir | VIH | List with clinical criteria and/or conditions | Complete | November 29, 2007 | May 14, 2008 |
| Izba | Solution ophtalmique travoprost | Glaucome à angle ouvert | Reimburse with clinical criteria and/or conditions | Complete | March 1, 2017 | October 25, 2017 |
| Janumet | Phosphate de sitagliptine monohydraté/chlorhydrate de metformine | Diabète de type 2 | List with clinical criteria and/or conditions | Complete | November 4, 2009 | June 23, 2010 |
| Januvia | Phosphate de sitagliptine | Diabète de type 2 | List with clinical criteria and/or conditions | Complete | October 29, 2009 | June 23, 2010 |
| Januvia | Phosphate de sitagliptine | Diabète de type 2 | Do not list | Complete | December 20, 2007 | June 18, 2008 |
| Jardiance | Empagliflozine | Diabète sucré type 2 à haut risque cardiovasculaire | Reimburse with clinical criteria and/or conditions | Complete | April 27, 2016 | October 26, 2016 |
| Jardiance | Empagliflozine | Diabète sucré de type 2 | List with clinical criteria and/or conditions | Complete | April 23, 2015 | October 15, 2015 |
| Jentadueto | Linagliptine/metformine | Diabète de type 2 | List with criteria/condition | Complete | March 8, 2013 | October 17, 2013 |
| Jetrea | Ocriplasmine | Adhérence vitréomaculaire | List with criteria/condition | Complete | June 6, 2013 | December 20, 2013 |
| Jinarc | Tolvaptan | Polykystose rénale à caractère autosomique dominant (ADPKD) | Do not list | Complete | May 29, 2015 | February 24, 2016 |
| Jorveza | budésonide | œsophagite à éosinophiles chez l'adulte – entretien | En attente | |||
| Jorveza | budésonide | Œsophagite à éosinophiles, adultes | Active | November 8, 2019 | ||
| Jublia | éfinaconazole | Onychomycose | Do not reimburse | Complete | August 2, 2018 | May 23, 2019 |
| Juluca | Dolutégravir rilpivirine | Infection par le VIH | Reimburse with clinical criteria and/or conditions | Complete | December 21, 2017 | June 20, 2018 |
| Jurnista | Chlorhydrate d'hydromorphone | Douleur chronique (de modérée à intense) | Do not list | Complete | December 4, 2009 | May 19, 2010 |
| Juxtapid | Lomitapide | hypercholestérolémie familiale | Do not list | Complete | July 8, 2014 | April 17, 2015 |
| Kalydeco | Ivacaftor | Fibrose kystique, mutation R117H du gène CFTR | List with criteria/condition | Complete | May 8, 2015 | November 19, 2015 |
| Kalydeco | Ivacaftor | Fibrose kystique (mutation G551D) | List with criteria/condition | Complete | September 27, 2012 | March 22, 2013 |
| Kalydeco | Ivacaftor | Fibrose cystique (mutations de CFTR) | List with criteria/condition | Complete | May 1, 2014 | December 19, 2014 |
| Kanuma | sebelipase alfa | Déficit en lipase acide lysosomique | Reimburse with clinical criteria and/or conditions | Complete | November 2, 2017 | September 26, 2018 |
| Kazano | Alogliptine alliée à metformine | diabète de type 2 | Do not list | Complete | January 30, 2014 | January 15, 2015 |
| Kevzara | sarilumab | Polyarthrite rhumatoïde | Reimburse with clinical criteria and/or conditions | Complete | October 12, 2016 | April 18, 2017 |
| Kivexa | Abacavir/lamivudine | Infection au VIH | List in a similar manner to other drugs in class | Complete | July 26, 2005 | December 7, 2005 |
| Komboglyze | Saxagliptine et metformine | Diabète de type 2 | List with criteria/condition | Complete | August 23, 2013 | June 20, 2014 |
| Komboglyze | Saxagliptine et metformine | Diabète de type 2 | Withdrawn | June 6, 2013 | ||
| Kuvan | Dichlorhydrate de saproptérine | Phénylcétonurie | Do not list | Complete | July 8, 2010 | January 26, 2011 |
| Kuvan | Sapropterin dihydrochloride | Phénylcénoturie | Reimburse with clinical criteria and/or conditions | Complete | February 1, 2016 | October 26, 2016 |
| Kuvan | Dichlorhydrate de saproptérine | Phénylcétonurie | Complete | June 1, 2011 | ||
| Kynmobi | chlorhydrate d'apomorphine | maladie de Parkinson | Active | June 25, 2020 | ||
| Kynmobi | chlorhydrate d'apomorphine | Maladie de Parkinson | Withdrawn | February 25, 2019 | ||
| Lancora | Ivabradine | Insuffisance cardiaque, classes NYHA II à III | Reimburse with clinical criteria and/or conditions | Complete | November 8, 2016 | May 24, 2017 |
| Lantus | Insuline glargine (source ADNr) | Diabète de type 2 | Do not list | Complete | February 11, 2005 | September 28, 2005 |
| Lantus | Insuline glargine (source ADNr) | Diabète de type 1 et 2 | Do not list | Complete | March 27, 2006 | October 25, 2006 |
| Lantus | Insuline glargine (source ADNr) | Diabète de type 1 et 2 | Complete | June 9, 2009 | ||
| Lapelga | Pegfilgrastim | Neutropénie fébrile | Complete | February 23, 2018 | ||
| Latuda | Lurasidone | Schizophrénie | Do not list | Complete | July 3, 2012 | January 23, 2013 |
| Latuda | Lurasidone | Schizophrénie | List with criteria/condition | Complete | May 9, 2013 | December 20, 2013 |
| Latuda | lurasidone | Trouble bipolaire de type I | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | NotFiled | ||
| Lemtrada | Alemtuzumab | Sclérose en plaques rémittente | Withdrawn | October 1, 2013 | ||
| Lemtrada | Alemtuzumab | Sclérose en plaques cyclique | List with criteria/condition | Complete | November 27, 2014 | June 18, 2015 |
| Levemir | Insuline détémir | Diabète | Withdrawn | February 2, 2009 | ||
| Levemir | Insuline détémir | Diabète | Do not list | Complete | March 10, 2009 | August 20, 2009 |
| Levemir | Insuline détémir | Diabète | Do not list | Complete | December 19, 2005 | August 2, 2006 |
| Levemir | Insuline détémir | Diabète de type 1, pédiatrique | Do not list | Complete | March 10, 2009 | August 20, 2009 |
| pdp-levETIRAcetam | lévétiracétam | épilepsie | Active | July 17, 2020 | ||
| Lixiana NVAF | Edoxaban | Fibrillation auriculaire non valvulaire, prévention des accidents vasculaires cérébraux et des embolies systémiques | Reimburse with clinical criteria and/or conditions | Complete | September 9, 2016 | March 21, 2017 |
| Lixiana VTE | Edoxaban | Thromboembolie veineuse, traitement et prevention de récurrence | Reimburse with clinical criteria and/or conditions | Complete | September 9, 2016 | May 25, 2017 |
| Lodalis | Chlorhydrate de colésévélam | Hypercholestérolémie | Do not list at the submitted price | Complete | April 27, 2012 | December 19, 2012 |
| Lokelma | Cyclosilicate de zirconium sodique | Hyperkaliémie chez les adultes | Do not reimburse | Complete | May 17, 2019 | March 25, 2020 |
| Lotemax | Étabonate de lotéprednol | Inflammation postopératoire après une chirurgie de la cataracte | Do not list | Complete | December 2, 2009 | May 19, 2010 |
| Lucentis | Ranibizumab | Dégénération maculaire liée à l'âge | List with clinical criteria and/or conditions | Complete | July 12, 2007 | March 27, 2008 |
| Lucentis | Ranibizumab injectable | œdème maculaire secondaire à une occlusion veineuse rétinienne | List with clinical criteria and/or conditions | Complete | April 25, 2012 | October 18, 2012 |
| Lucentis | Ranibizumab | Néovascularisation choroïdienne due à la myopie | List with criteria/condition | Complete | February 28, 2014 | February 19, 2015 |
| Lucentis | Ranibizumab | œdème maculaire diabétique | List with clinical criteria and/or conditions | Complete | September 14, 2011 | March 19, 2012 |
| Luxturna | voretigène néparvovec | Perte visuelle due à une dystrophie rétinienne héréditaire | Active | April 23, 2020 | ||
| Lyrica | Prégabaline | Douleur neuropathique | Do not list | Complete | June 27, 2005 | January 25, 2006 |
| Lyrica | Prégabaline | Neuropathie périphérique diabétique | Do not list | Complete | March 20, 2009 | September 23, 2009 |
| Pantoloc M | Pantoprazole magnésique | Réduction de la sécrétion d'acide gastrique | List in a similar manner to other drugs in class | Complete | March 17, 2006 | July 20, 2006 |
| Macugen | Pegaptanib sodique | Dégénérescence maculaire liée à l'âge | Do not list | Complete | October 20, 2005 | May 25, 2006 |
| Mavenclad | cladribine | Sclérose en plaques cyclique | Reimburse with clinical criteria and/or conditions | Complete | December 1, 2017 | October 24, 2018 |
| Maviret | Glécaprévir/pibréntasvir | Hépatite C chronique | Reimburse with clinical criteria and/or conditions | Complete | June 9, 2017 | January 23, 2018 |
| Mayzent | siponimod | La sclérose en plaques progressive secondaire | Reimburse with clinical criteria and/or conditions | Complete | September 26, 2019 | July 21, 2020 |
| MDK-Nitisinone | nitisinone | La tyrosinémie héréditaire de type 1 | Reimburse with clinical criteria and/or conditions | Complete | September 29, 2017 | April 25, 2018 |
| Mictoryl | chlorhydrate de propivérine | Vessie hyperactive | Reimburse with clinical criteria and/or conditions | Complete | October 14, 2016 | April 19, 2017 |
| Mifegymiso | Mifépristone et misoprostol | Interruption médicale de grossesse | Reimburse | Complete | October 7, 2016 | April 18, 2017 |
| Mifégymiso | Mifépristone et misoprostol | Interruption médicale de la grossesse (âge gestationnel jusqu’éa 49 jours) | Withdrawn | February 12, 2016 | ||
| mirabégron | Myrbetriq | Vessie hyperactive | List with criteria/condition | Complete | November 27, 2013 | November 12, 2014 |
| Monoferric | Fer-isomaltoside 1000 | Anémie ferriprive | Reimburse with clinical criteria and/or conditions | Complete | June 26, 2019 | March 25, 2020 |
| Monoprost | latanoprost | glaucome et hypertension oculaire | Reimburse with clinical criteria and/or conditions | Complete | October 25, 2017 | April 24, 2018 |
| Movapo | chlorhydrate d’apomorphine | Maladie de Parkinson | Reimburse with clinical criteria and/or conditions | Complete | July 6, 2017 | January 23, 2018 |
| Mozobil | Plérixafor | Mobilisation des cellules souches hématopoïétiques dans le contexte du lymphome malin non hodgkinien et du myélome multiple | Do not list | Complete | January 24, 2012 | September 26, 2012 |
| Multaq | Chlorhydrate de dronédarone | Fibrillation auriculaire | Do not list | Complete | September 18, 2009 | May 27, 2010 |
| Myfortic | Mycophénolate sodique | Rejet d'organes après une allogreffe rénale, prophylaxie | List in a similar manner to other drugs in class | Complete | March 3, 2005 | July 8, 2005 |
| Myozyme | Alglucosidase | Maladie de Pompe | List with clinical criteria and/or conditions | Complete | October 10, 2006 | June 14, 2007 |
| Myrbetriq | Mirabégron | Vessie hyperactive | Withdrawn | March 8, 2013 | ||
| Naglazyme | Galsulfase (Drug Plan Submission) | mucopolysaccharidose de type VI | List with clinical criteria and/or conditions | Complete | August 20, 2015 | February 19, 2016 |
| Nesina | Alogliptine | diabète de type 2 | Do not list | Complete | January 30, 2014 | January 15, 2015 |
| Neulasta | Pegfilgrastim | Neutropénie | List with clinical criteria and/or conditions | Complete | March 29, 2004 | October 27, 2004 |
| Neupro | Rotigotine | Maladie de Parkinson | Do not list | Complete | July 31, 2013 | May 28, 2014 |
| Neupro | Rotigotine | Maladie de Parkinson | List with clinical criteria and/or conditions | Complete | May 21, 2015 | November 19, 2015 |
| Nexavar | Sorafénib (comprimés) | Cancer, hypernéphrome | Do not list | Complete | July 31, 2006 | February 28, 2007 |
| Nexplanon | étonogestrel | Prévention de la grossesse | Reimburse with clinical criteria and/or conditions | Active | June 3, 2020 | October 20, 2020 |
| Nitisinone | Nitisinone | Tyrosinémie de type 1 | Reimburse with clinical criteria and/or conditions | Complete | January 25, 2018 | August 23, 2018 |
| Norprolac | Chlorhydrate de quinagolide | Hyperprolactinémie | Do not list | Complete | December 16, 2004 | September 28, 2005 |
| Norprolac | Chlorhydrate de quinagolide | Hyperprolactinémie | List with clinical criteria and/or conditions | Complete | November 23, 2005 | May 17, 2006 |
| Nplate | Romiplostim | Purpura thrombopénique idiopathique (chronique immun) | Do not list | Complete | September 29, 2009 | May 27, 2010 |
| Nucala | mépolizumab | L'asthme éosinophile grave | Reimburse with clinical criteria and/or conditions | Complete | October 24, 2018 | March 27, 2019 |
| Nucala | Mépolizumab | Asthme, grave à éosinophiles | Reimburse with clinical criteria and/or conditions | Complete | December 18, 2015 | June 16, 2016 |
| Nucynta | Chlorhydrate de tapentadol | douleur intense | Do not reimburse | Complete | April 17, 2018 | October 23, 2018 |
| NuvaRing | Étonogestrel et éthinylestradiol | Anneau contraceptif | List with clinical criteria and/or conditions | Complete | May 5, 2006 | November 29, 2006 |
| Ocaliva | Acide obéticholique | Cholangite biliaire primitive | Reimburse with clinical criteria and/or conditions | Complete | December 22, 2016 | July 25, 2017 |
| Ocrevus | ocrélizumab | Forme progressive primaire de sclérose en plaques | Reimburse with clinical criteria and/or conditions | Complete | October 26, 2017 | April 26, 2018 |
| Ocrevus | ocrélizumab | Sclérose en plaques cyclique | Reimburse with clinical criteria and/or conditions | Complete | May 16, 2017 | November 21, 2017 |
| Odefsey | Emtricitabine, rilpivirine et ténofovir alafénamide | Infection VIH-1 | Reimburse with clinical criteria and/or conditions | Complete | November 24, 2016 | May 25, 2017 |
| Ofev | Nintedanib | Fibrose pulmonaire idiopathique (FPI) | List with clinical criteria and/or conditions | Complete | April 23, 2015 | October 15, 2015 |
| Ofev | Active | July 24, 2020 | ||||
| Olmetec Plus | Olmésartan médoxomil et hydrochlorothiazide | Hypertension | List in a similar manner to other drugs in class | Complete | November 28, 2008 | May 27, 2009 |
| Olmetec | Olmésartan médoxomil | Hypertension | List in a similar manner to other drugs in class | Complete | November 28, 2008 | May 27, 2009 |
| Olumiant | Baricitinib | Polyarthrite rhumatoïde | Reimburse with clinical criteria and/or conditions | Complete | December 20, 2018 | August 2, 2019 |
| Omnaris | Ciclésonide en vaporisateur nasal | Rhinite allergique (saisonnière et perannuelle) | Do not list | Complete | May 7, 2008 | November 12, 2008 |
| Omnitrope | Somatropine (d'origine ADNr) | Déficit en hormone de croissance chez l'enfant et l'adulte | Complete | June 12, 2009 | ||
| Onbrez | Indacatérol | Maladie pulmonaire obstructive chronique (MPOC), bronchodilatateur d'entretien | List in a similar manner | Complete | February 29, 2012 | August 16, 2012 |
| Onglyza | Saxagliptine | Diabète sucré (type 2) | Do not list | Complete | November 9, 2009 | June 17, 2010 |
| Onglyza | Saxagliptine | Diabète de type 2 | List with criteria/condition | Complete | May 9, 2013 | November 15, 2013 |
| Onglyza | Saxagliptine | Diabète de type 2 | Withdrawn | May 28, 2012 | ||
| Onpattro | Patisiran | La polyneuropathie dans l’amylose de la transthyrétine héréditaire | Reimburse with clinical criteria and/or conditions | Complete | January 25, 2019 | July 25, 2019 |
| Onsolis | Citrate de fentanyl | Douleur paroxystique, cancer (adulte) | Withdrawn | May 10, 2011 | ||
| Onsolis | Citrate de fentanyl | Douleur paroxystique, cancer (adulte) | Do not list | Complete | August 22, 2011 | February 15, 2012 |
| Onstryv | safinamide | Maladie de Parkinson | Do not reimburse | Complete | May 29, 2019 | March 25, 2020 |
| Restasis (émulsion ophtalmique) | Cyclosporine | Syndrome de l'œil sec, de modéré à modérément grave | Do not list | Complete | December 17, 2010 | July 18, 2011 |
| Opsumit | Macitentan | Hypertension pulmonaire | List with clinical criteria and/or conditions | Complete | December 18, 2015 | January 28, 2015 |
| Oralair | Extrait allergénique de pollen de graminées | Rhinite allergique (pollen de graminées) | List with criteria/condition | Complete | September 21, 2012 | March 20, 2013 |
| Orencia | Abatacept | Arthrite juvénile idiopathique; arthrite chronique juvénile | List with clinical criteria and/or conditions | Complete | August 29, 2008 | April 22, 2009 |
| Orencia | Abatacept | Polyarthrite rhumatoïde | List with clinical criteria and/or conditions | Complete | November 29, 2012 | July 18, 2013 |
| Orencia | Abatacept | Polyarthrite rhumatoïde | List in a similar manner | Complete | December 2, 2009 | June 17, 2010 |
| Orencia | Abatacept | Polyarthrite rhumatoïde | List with clinical criteria and/or conditions | Complete | October 26, 2006 | June 27, 2007 |
| Orfadin | nitisinone | Tyrosinémie héréditaire de type 1 | Reimburse with clinical criteria and/or conditions | Complete | August 29, 2017 | February 21, 2018 |
| Orilissa | élagolix | Le traitement des douleurs modérées à intenses associées à l'endométriose | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | NotFiled | ||
| Orkambi | lumacaftor/ivacaftor | Fibrose kystique, mutation F.508del chez les patients âgés de 6 ans et plus | Do not reimburse | Complete | February 22, 2018 | September 26, 2018 |
| Orkambi | lumacaftor/ivacaftor | Fibrose kystique, mutation CFTR F508del | Do not reimburse | Complete | January 28, 2016 | October 26, 2016 |
| Otezla | Apremilast | Arthrite, psoriatique | List with criteria/condition | Complete | June 8, 2015 | December 17, 2015 |
| Otezla | Apremilast | Psoriasis, en plaques modérées à sévères | Do not list | Complete | October 8, 2014 | July 22, 2015 |
| Otezla | Aprémilast | Psoriasis, modéré à sévère | Reimburse with clinical criteria and/or conditions | Complete | March 3, 2016 | October 26, 2016 |
| Ozanex | ozénoxacine | Impétigo | Do not reimburse | Complete | January 25, 2018 | October 24, 2018 |
| Ozempic | Sémaglutide | Diabète de type 2 | Reimburse with clinical criteria and/or conditions | Complete | November 23, 2018 | May 15, 2019 |
| Ozurdex | Dexaméthasone | Œdème maculaire diabétique | Do not reimburse | Complete | September 26, 2017 | October 24, 2018 |
| Ozurdex | Implant intravitréen de dexaméthasone | Œdème maculaire secondaire à une occlusion veineuse rétinienne | Do not list | Complete | September 1, 2011 | April 25, 2012 |
| Pegasys RBV | Peginterféron alfa-2a et ribavirine | Hépatite C chronique | List in a similar manner to other drugs in class | Complete | May 14, 2004 | October 14, 2004 |
| Pheburane | Phénylbutyrate de sodium | Troubles du cycle de l'urée | Complete | October 20, 2015 | ||
| Picato | Mébutate d’ingénol | Kératose sénile | Do not list | Complete | May 9, 2013 | January 22, 2014 |
| Picato | Mébutate d'ingénol | Kératose actinique | Complete | May 26, 2014 | ||
| Pifeltro | doravirine | infection due au VIH-1 | Reimburse with clinical criteria and/or conditions | Complete | November 16, 2018 | May 14, 2019 |
| Plegridy | Peginterféron béta-1a | Sclérose en plaques cyclique | List with criteria/condition | Complete | June 26, 2015 | December 17, 2015 |
| Teveten Plus | Mésylate d'éprosartan et hydrochlorothiazide | Hypertension essentielle | List in a similar manner to other drugs in class | Complete | July 8, 2004 | December 15, 2004 |
| Pradaxa | Dabigatran etexilate | Prévention de l'AVC et de l'embolie systémique en contexte de fibrillation auriculaire | Cancelled | May 31, 2010 | ||
| Pradaxa | Dabigatran etexilate | Prévention de l'AVC et de l'embolie systémique en contexte de fibrillation auriculaire | List with clinical criteria and/or conditions | Complete | October 28, 2010 | June 22, 2011 |
| Pradaxa | Dabigatran etexilate | Prévention de la thromboembolie veineuse | Do not list | Complete | July 8, 2008 | January 28, 2009 |
| Pradaxa | Dabigatran etexilate | Prévention de l'AVC et de l'embolie systémique en contexte de fibrillation auriculaire | List with clinical criteria and/or conditions | Complete | March 18, 2013 | July 18, 2013 |
| Praluent | Alirocumab | Hypercholestérolémie primaire (non-familiale et hétérozygote familiale), dyslipidémie mixte | Reimburse with clinical criteria and/or conditions | Complete | January 12, 2016 | July 20, 2016 |
| Praxbind | Idarucizumab (demande d'un régime d'assurance) | neutralisation de l’effet anticoagulant du dabigatran | Withdrawn | May 30, 2016 | ||
| Prevymis | létermovir | Infection au cytomégalovirus, prophylaxie | Reimburse with clinical criteria and/or conditions | Complete | December 7, 2017 | June 20, 2018 |
| Prexige | Lumiracoxib | Arthrose du genou | Do not list | Complete | December 15, 2006 | July 25, 2007 |
| Prezcobix | Darunavir/cobicistat | Infection par le VIH | List with criteria/condition | Complete | May 22, 2014 | March 18, 2015 |
| Prezista | Darunavir | Infection par le VIH | List with clinical criteria and/or conditions | Complete | August 29, 2006 | February 14, 2007 |
| Prezista | Darunavir | Infection par le VIH (enfant) | List with clinical criteria and/or conditions | Complete | December 22, 2009 | June 17, 2010 |
| Prezista | Darunavir | Infection par le VIH (patient jamais traité) | List with clinical criteria and/or conditions | Complete | March 27, 2009 | October 14, 2009 |
| Pristiq | Succinate de desvenlafaxine | Trouble dépressif majeur (TDM) | Do not list | Complete | March 5, 2009 | September 23, 2009 |
| Probuphine | chlorhydrate de buprénorphine | Traitement de la dépendance aux opioïdes | Reimburse with clinical criteria and/or conditions | Complete | December 21, 2017 | August 22, 2018 |
| Procysbi | Bitartrate de cystéamine | Cystinose néphropathique | Reimburse with clinical criteria and/or conditions | Complete | August 8, 2017 | January 24, 2018 |
| Prolia | Denosumab (Déposé par un régime d’assurance médicaments) | Ostéoporose chez les hommes | List with clinical criteria and/or conditions | Complete | March 10, 2015 | September 21, 2015 |
| Prolia | Dénosumab | Ostéoporose, femmes ménopausées | List with clinical criteria and/or conditions | Complete | August 26, 2010 | March 30, 2011 |
| Prolia | Dénosumab | Ostéoporose, femmes postménopausiques | Reimburse with clinical criteria and/or conditions | Complete | October 26, 2015 | May 20, 2016 |
| Quinsair | Lévofloxacine | Fibrose kystique compliquée par des infections pulmonaires chroniques dues à Pseudomas æruginosa | Reimburse with clinical criteria and/or conditions | Complete | May 31, 2016 | November 21, 2016 |
| Radicava | édavarone | Sclérose latérale amyotrophique | Reimburse with clinical criteria and/or conditions | Complete | July 5, 2018 | March 27, 2019 |
| Ralivia | Chlorhydrate de tramadol | Douleur | Do not list | Complete | October 29, 2007 | June 25, 2008 |
| RAPAFLO | Silodosine | Hyperplasie bénigne de la prostate | Do not list | Complete | October 25, 2011 | April 19, 2012 |
| Raptiva | Efalizumab | Psoriasis en plaques chronique, de modéré à grave | Complete | June 19, 2007 | ||
| Raptiva | Efalizumab | Psoriasis en plaques chronique, de modéré à grave | List with clinical criteria and/or conditions | Complete | October 25, 2005 | August 24, 2006 |
| Rasilez | Aliskirène | Hypertension | Do not list | Complete | November 30, 2007 | June 25, 2008 |
| Ravicti | Phénylbutyrate de glycérol | Troubles du cycle de l’urée | Reimburse with clinical criteria and/or conditions | Complete | August 30, 2016 | March 21, 2017 |
| Rebif | Interféron (IFN) bêta-1a | Syndrome clinique isolé | Do not list | Complete | March 8, 2013 | August 15, 2013 |
| Reblozyl | luspatercept | ReblozylMD (luspatercept pour injection) est indiqué dans le traitement des patients adultes présentant une anémie dépendante des transfusions de globules rouges (GR) associée à une bêta (β)–thalassémie | En attente | |||
| Relistor | Bromure de méthylnaltrexone | Constipation, causée par un opioïde | Do not list | Complete | May 7, 2008 | January 28, 2009 |
| Relpax | Bromhydrate d’élétriptan | Migraine | Do not list | Complete | September 21, 2004 | March 23, 2005 |
| Remicade | Infliximab | Colite ulcéreuse | Do not list | Complete | September 29, 2008 | April 22, 2009 |
| Remodulin | Sodium de tréprostinil | Hypertension pulmonaire (patients de catégories III et IV de la NYHA) | List with clinical criteria and/or conditions | Complete | February 24, 2006 | July 20, 2006 |
| Remodulin | Sodium de tréprostinil | Hypertension pulmonaire (patients de catégories III et IV de la NYHA) | Do not list | Complete | July 14, 2004 | November 17, 2004 |
| Remsima | Infliximab | Spondylarthrite ankylosante, psoriasis en plaques, arthrite psoriasique, arthrite rhumatoïde | Withdrawn | May 30, 2014 | ||
| Renflexis | infliximab | arthrite rhumatoïde, spondylarthrite ankylosante, maladie de Crohn chez l’adulte, maladie de Crohn pédiatrique, maladie de Crohn fistuleuse, colite ulcéreuse chez l’adulte, colite ulcéreuse pédiatrique, arthrite psoriasique, psoriasis en plaques | Reimburse with clinical criteria and/or conditions | Complete | September 5, 2017 | February 20, 2018 |
| Repatha | Evolocumab | hyperlipidémie primaire et dyslipidémie mixte | Reimburse with clinical criteria and/or conditions | Complete | February 17, 2017 | November 22, 2017 |
| Repatha | Évolocumab | Hyperlipédémie primaire, dyslipédémie mixte, hypercholestérolémie familiale homozygote | List with clinical criteria and/or conditions | Complete | June 30, 2015 | February 19, 2016 |
| Replagal | Agalsidase alfa | Maladie de Fabry | Do not list | Complete | February 19, 2004 | November 24, 2004 |
| Resotran | Prucalopride | Constipation chronique | Do not list | Complete | January 30, 2012 | July 19, 2012 |
| Spiriva Respimat | Bromure de tiotropium | Maladie pulmonaire obstructive chronique (MPOC) | List with clinical criteria and/or conditions | Complete | December 23, 2014 | July 16, 2015 |
| Revatio | Citrate de sildénafil | Hypertension pulmonaire (catégories II et III de l'OMS) | List in a similar manner | Complete | September 20, 2006 | February 14, 2007 |
| Revestive | téduglutide | Syndrome de l’intestin court (SIC) | Reimburse with clinical criteria and/or conditions | Complete | November 26, 2015 | July 27, 2016 |
| Revestive | Téduglutide | Syndrome du grêle court (SGC), pédiatrique | Reimburse with clinical criteria and/or conditions | Complete | May 29, 2019 | November 19, 2019 |
| Revolade | Eltrombopag | Thrombocytopénie associée à l’hépatite C | List with criteria/condition | Complete | March 31, 2014 | March 18, 2015 |
| Revolade | Eltrombopag olamine | Purpura thrombopénique chronique immunitaire (idiopathique) | Do not list | Complete | April 26, 2011 | October 24, 2011 |
| Revolade | eltrombopag | Anémie aplastique grave | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | NotFiled | ||
| Rexulti | Brexpiprazole | Schizophrénie | Reimburse with clinical criteria and/or conditions | Complete | February 3, 2017 | November 22, 2017 |
| Reyataz | Atazanavir | Infection par le VIH | List in a similar manner to other drugs in class | Complete | December 16, 2003 | May 27, 2004 |
| Rinvoq | upadacitinib | Polyarthrite rhumatoïde | Reimburse with clinical criteria and/or conditions | Complete | July 4, 2019 | February 4, 2020 |
| Rituxan | Rituximab | Granulomatose avec polyangéite (GPA) et polyangéite microscopique, induction de la rémission (adulte) | List with clinical criteria and/or conditions | Complete | February 24, 2012 | August 16, 2012 |
| Rituxan | Rituximab | Polyarthrite rhumatoïde | List with clinical criteria and/or conditions | Complete | June 26, 2006 | February 14, 2007 |
| Rosiver | Ivermectine | Rosacée | List with criteria/condition | Complete | April 30, 2015 | November 19, 2015 |
| Ruzurgi | syndrome myasthénique de Lambert-Eaton | Received | October 5, 2020 | |||
| Rybelsus | sémaglutide | Comme traitement d'appoint à une alimentation saine et à l'activité physique pour améliorer la maitrise de la glycémie chez l'adulte atteint de diabète de type 2 : en monothérapie si la metformine est jugée inappropriée en raison d'une intolérance ou de contrindications; en combinaison avec d'autres produits médicinaux de traitement du diabète. | En attente | |||
| Samsca | Tolvaptan | Hyponatrémie, non hypovolémique | Do not list | Complete | July 3, 2012 | February 13, 2013 |
| Saphris | Asénapine | Schizophrénie | Do not list | Complete | December 12, 2011 | June 14, 2012 |
| Saphris | Asénapine | Trouble bipolaire de type I | List with clinical criteria and/or conditions | Complete | December 12, 2011 | June 14, 2012 |
| Sativex | Delta-9-tétrahydrocannabinol et cannabidiol | Douleur cancéreuse (analgésie d'appoint à la dose maximale tolérée d'opioïdes) | Do not list | Complete | August 7, 2007 | February 20, 2008 |
| Sativex | Delta-9-tétrahydrocannabinol et cannabidiol | Douleur neuropathique (appoint) en contexte de SP | Do not list | Complete | February 27, 2007 | September 26, 2007 |
| Sebivo | Telbivudine | Hépatite B (chronique) | Do not list | Complete | December 4, 2006 | September 26, 2007 |
| Seebri | Bromure de glycopyrronium | Maladie pulmonaire obstructive chronique (MPOC), traitement bronchodilatateur d'entretien | List with criteria/condition | Complete | November 30, 2012 | May 15, 2013 |
| Segluromet | Ertugliflozine et chlorhydrate de metformine | Diabète de type 2 | Do not reimburse | Complete | April 30, 2018 | January 23, 2019 |
| Semglee | Insuline glargine | Diabète sucré, type 1 et 2 | Withdrawn | November 14, 2018 | ||
| Sensipar | Chlorhydrate de cinacalcet | Hyperparathyroïdisme secondaire dans la maladie rénale chronique | Do not list | Complete | August 20, 2004 | March 23, 2005 |
| Signifor | Pasiréotide diaspartate | Maladie de Cushing | Do not list | Complete | February 27, 2014 | February 24, 2015 |
| Siliq | Brodalumab | Psoriasis en plaques, modéré ou grave | Reimburse with clinical criteria and/or conditions | Complete | December 14, 2017 | June 20, 2018 |
| Silkis | Calcitriol | Psoriasis en plaques, de léger à modéré | Do not list | Complete | March 15, 2010 | September 22, 2010 |
| Simbrinza | Brinzolamide / brimonidine | Glaucome et hypertension oculaire | List | Complete | November 3, 2014 | June 17, 2015 |
| Simponi | Golimumab | Spondylarthrite ankylosante | List in a similar manner | Complete | September 3, 2009 | March 17, 2010 |
| Simponi | Golimumab | Polyarthrite rhumatoïde | List in a similar manner | Complete | September 3, 2009 | March 17, 2010 |
| Simponi | Golimumab | Rectocolite hémorragique | Do not list at the submitted price | Complete | July 12, 2013 | March 19, 2014 |
| Simponi | Golimumab | Arthrite psoriasique | List in a similar manner | Complete | September 3, 2009 | March 17, 2010 |
| Sivextro | Phosphate de tédizolid | Infections bactériennes aigües de la peau et des structures cutanées | Withdrawn | January 16, 2015 | ||
| Skyrizi | risankizumab | Le psoriasis en plaques modéré à grave | Reimburse with clinical criteria and/or conditions | Complete | October 22, 2018 | May 28, 2019 |
| Soliqua | lixisénatide et insuline glargine | Diabète de type 2 | Reimburse with clinical criteria and/or conditions | Complete | May 18, 2018 | December 24, 2018 |
| Soliris | Éculizumab | Syndrome hémolytique et urémique atypique | Do not list | Complete | January 7, 2013 | July 18, 2013 |
| Soliris | éculizumab | Le trouble du spectre de la neuromyélite optique | Reimburse with clinical criteria and/or conditions | Complete | February 25, 2020 | August 19, 2020 |
| Soliris | Éculizumab | Hémoglobinurie paroxystique nocturne | Do not list | Complete | September 18, 2009 | February 18, 2010 |
| Soliris | éculizumab | Myasthénie grave, adultes | Reimburse with clinical criteria and/or conditions | Active | April 1, 2020 | October 19, 2020 |
| Soliris | Éculizumab | syndrome hémolytique et urémique, atypique | Complete | February 9, 2015 | ||
| Somavert | Pegvisomant | Acromégalie | Do not list | Complete | January 25, 2006 | August 2, 2006 |
| Sovaldi | sofosbuvir | Hépatite C, chronique | Reimburse with clinical criteria and/or conditions | Complete | January 6, 2016 | May 18, 2016 |
| Sovaldi | Sofosbuvir | Hépatite C, chronique | List with criteria/condition | Complete | October 1, 2013 | August 18, 2014 |
| Spinraza | nusinersen | amyotrophie spinale | Reimburse with clinical criteria and/or conditions | Complete | June 28, 2017 | December 22, 2017 |
| Spinraza | Nusinersen | Amyotrophie spinale | Reimburse with clinical criteria and/or conditions | Complete | July 24, 2018 | February 27, 2019 |
| Spravato | chlorhydrate d'eskétamine | Trouble dépressif majeur chez les adultes | Active | June 24, 2019 | ||
| Spriafil | Posaconazole | Infections par aspergillus et candida | Do not list | Complete | May 24, 2007 | January 30, 2008 |
| Stalevo | Lévodopa, carbidopa et entacapone | Maladie de Parkinson | List in a similar manner | Complete | April 15, 2008 | October 16, 2008 |
| Steglatro | Diabète de type 2 | Do not reimburse | Complete | April 30, 2018 | January 23, 2019 | |
| Stelara | Ustekinumab | Psoriasis | List with clinical criteria and/or conditions | Complete | January 7, 2009 | June 17, 2009 |
| Stelara | Ustekinumab | Arthrite psoriasique | Do not list at the submitted price | Complete | October 30, 2013 | October 20, 2014 |
| Strattera | Chlorhydrate d'atomoxétine | Trouble de déficit de l’attention avec hyperactivité | Complete | September 25, 2006 | ||
| Strattera | Chlorhydrate d'atomoxétine | Trouble de déficit de l’attention avec hyperactivité | Do not list | Complete | January 25, 2005 | September 28, 2005 |
| Strensiq | Asfotase alfa | Hypophosphatasie, Durant l’enfance | List with criteria/condition | Complete | August 21, 2015 | March 23, 2016 |
| Stribild | Elvitégravir/cobicistat/emtricitabine/fumarate de ténofovir disoproxil | Infection par le VIH-1 | List with criteria/condition | Complete | November 30, 2012 | May 15, 2013 |
| Sublinox | Tartrate de zolpidem | Insomnie, traitement à court terme | Do not list | Complete | March 7, 2013 | September 25, 2013 |
| Sublocade | Buprénorphine | Traitement du trouble de consommation d'opioïdes | Reimburse with clinical criteria and/or conditions | Complete | December 20, 2018 | June 19, 2019 |
| Suboxone | Buprénorphine/naloxone | Dépendance aux opioïdes (traitement de substitution) | List with clinical criteria and/or conditions | Complete | March 6, 2008 | September 24, 2008 |
| Sunvepra | Asunaprévir | Hépatite C chronique | Reimburse with clinical criteria and/or conditions | Complete | February 13, 2015 | July 20, 2016 |
| Sutent | Sunitinib | Tumeur stromale gastro-intestinale | List with clinical criteria and/or conditions | Complete | July 20, 2006 | March 28, 2007 |
| Sutent | Malate de sunitinib | Cancer, adénocarcinome rénal métastatique | Do not list | Complete | September 20, 2006 | April 26, 2007 |
| Symdeko | tézacaftor/ivacaftor | Fibrose kystique, mutation(s) F508del | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | NotFiled | ||
| Symtuza | Darunavir/cobicistat/emtricitabine/ténofovir alafénamide | Infection par le VIH-1 | Reimburse with clinical criteria and/or conditions | Complete | December 22, 2017 | July 25, 2018 |
| Synjardy | Empagliflozine et metformine | Diabète de type 2 | Reimburse with clinical criteria and/or conditions | Complete | April 29, 2016 | October 25, 2016 |
| Takhzyro | lanadélumab | Angio-œdème héréditaire, prévention | Reimburse with clinical criteria and/or conditions | Complete | May 29, 2019 | November 19, 2019 |
| Taltz | ixékizumab | Spondylarthrite ankylosante | Reimburse with clinical criteria and/or conditions | Complete | September 20, 2019 | March 24, 2020 |
| Taltz | Ixékizumab | Psoriasis en plaques modéré à sévère | Reimburse with clinical criteria and/or conditions | Complete | March 23, 2016 | October 25, 2016 |
| Taltz | ixékizumab | Arthrite psoriasique évolutive | Reimburse with clinical criteria and/or conditions | Complete | February 20, 2018 | August 21, 2018 |
| Tarceva | Erlotinib | Cancer du poumon non à petites cellules | List with clinical criteria and/or conditions | Complete | July 19, 2005 | December 7, 2005 |
| Targin | Chlorhydrate d'oxycodone et chlorhydrate de naloxone | Douleur, de modérée à intense; soulagement de la constipation causée par les opioïdes | Do not list | Complete | July 5, 2011 | January 25, 2012 |
| Targin | Oxycodone / naloxone | Douleur, de modérée à intense; soulagement de la constipation causée par les opioïdes | Cancelled | November 30, 2010 | ||
| TBC | ofatumumab | sclérose en plaques récurrente | Active | August 25, 2020 | ||
| TBC | risdiplam | Amyotrophie spinale | En attente | |||
| TBC | filgotinib | polyarthrite rhumatoïde | Received | August 4, 2020 | ||
| TBC | infliximab | polyarthrite rhumatoïde, maladie de Crohn, colite ulcéreuse | Active | September 24, 2020 | ||
| TBC | ranolazine | angine de poitrine stable chez l'adulte | Active | August 17, 2020 | ||
| Tecfidera | Fumarate de diméthyle | Sclérose en plaques cyclique | List with criteria/condition | Complete | February 4, 2013 | September 25, 2013 |
| Technivie | ombitasvir/ paritaprévir/ ritonavir | hépatite C chronique, VHC de génotype 4 | List with clinical criteria and/or conditions | Complete | September 4, 2015 | March 18, 2016 |
| Tegsedi | inotersen | amylose héréditaire liée à la transthyrétine | Reimburse with clinical criteria and/or conditions | Complete | February 22, 2019 | December 18, 2019 |
| Telzir | Fosamprénavir calcique | Infection par le VIH | List in a similar manner to other drugs in class | Complete | January 24, 2005 | June 16, 2005 |
| Thelin | Sodium de sitaxsentan | Hypertension pulmonaire (classes II et III de l'OMS) | Do not list | Complete | June 22, 2007 | January 30, 2008 |
| Thelin | Sodium de sitaxsentan | Hypertension pulmonaire (classes II et III de l'OMS) | Do not list | Complete | May 5, 2008 | January 28, 2009 |
| Tivicay | Dolutégravir | Infection par le VIH | List | Complete | October 18, 2013 | August 18, 2014 |
| Toctino | Alitrétinoïne | Eczéma | List with clinical criteria and/or conditions | Complete | May 6, 2011 | October 24, 2011 |
| Toviaz | Fumarate de fésotérodine | Vessie hyperactive | List in a similar manner | Complete | April 27, 2012 | October 18, 2012 |
| Trajenta | Linagliptine | Diabète de type 2 | List with clinical criteria and/or conditions | Complete | August 23, 2011 | February 15, 2012 |
| Tramacet | Chlorhydrate de tramadol et acétaminophène | Douleur aigüe | Do not list | Complete | October 2, 2006 | May 17, 2007 |
| Translarna | ataluren | La dystrophinopathie | Cancelled | |||
| Trelstar | Pamoate de triptoréline | Cancer de la prostate | List in a similar manner to other drugs in class | Complete | February 27, 2006 | July 20, 2006 |
| Tremfya | Psoriasis en plaques de modéré à sévère | Reimburse with clinical criteria and/or conditions | Complete | August 25, 2017 | February 21, 2018 | |
| Tresiba | insuline dégludec | Diabète sucré, types 1 et 2 | Reimburse with clinical criteria and/or conditions | Complete | May 31, 2017 | November 20, 2017 |
| Tridural | Chlorhydrate de tramadol | Douleur | Do not list | Complete | November 29, 2007 | April 17, 2008 |
| Trintellix | bromhydrate de vortioxétine | trouble dépressif majeur (TDM) chez les adultes | Reimburse with clinical criteria and/or conditions | Complete | May 1, 2019 | February 12, 2020 |
| Trintellix | Vortioxetine | Trouble dépressif majeur | Withdrawn | October 31, 2014 | ||
| Triumeq | Dolutégravir / abacavir / lamivudine | Infection par le VIH | List with criteria/condition | Complete | July 31, 2014 | April 17, 2015 |
| Trosec | Chlorure de trospium | Vessie hyperactive | List with clinical criteria and/or conditions | Complete | March 24, 2006 | August 24, 2006 |
| Trulicity | dulaglutide | Diabète sucré, type 2 | Reimburse with clinical criteria and/or conditions | Complete | December 22, 2015 | June 16, 2016 |
| Truvada | Emtricitabine/fumarate de ténofovir disoproxil | Infection par le VIH | List with clinical criteria and/or conditions | Complete | May 29, 2006 | October 25, 2006 |
| Truvada | Emtricitabine/fumarate de ténofovir disoproxil | Infection par le VIH | List with clinical criteria and/or conditions | Complete | July 7, 2008 | December 17, 2008 |
| Truvada | Emtricitabine/fumarate de ténofovir disoproxil | Infection par le VIH, prophylaxie préexposition | Reimburse with clinical criteria and/or conditions | Complete | March 3, 2016 | August 24, 2016 |
| Twynsta | Telmisartan et amlodipine | Hypertension essentielle | Cancelled | July 9, 2010 | ||
| Twynsta | Telmisartan et amlodipine | Hypertension essentielle | List | Complete | August 23, 2011 | December 16, 2011 |
| Tysabri | Natalizumab | Sclérose en plaques cyclique | List with clinical criteria and/or conditions | Complete | May 6, 2008 | February 25, 2009 |
| Tysabri | Natalizumab | Sclérose en plaques cyclique | Do not list | Complete | October 26, 2006 | April 26, 2007 |
| Uloric | Fébuxostat | Goutte | List with clinical criteria and/or conditions | Complete | October 27, 2010 | April 25, 2011 |
| Uptravi | Sélexipag | Hypertension artérielle pulmonaire (OMS) de classe II et III | Reimburse with clinical criteria and/or conditions | Complete | March 31, 2016 | October 28, 2016 |
| Vantas | Acétate d´histréline | Cancer, prostate | Do not list | Complete | September 20, 2006 | April 26, 2007 |
| Vascepa | acide éthyl-eicosapentaénoïque | Évènements ischémiques chez les patients traités aux statines | Reimburse with clinical criteria and/or conditions | Complete | June 17, 2019 | July 16, 2020 |
| Velphoro | oxyhydroxyde sucro-ferrique | hyperphosphatémie, insuffisance rénale terminale | Reimburse with clinical criteria and/or conditions | Complete | June 12, 2018 | January 2, 2019 |
| Veltassa | patiromer | hyperkaliémie chez l'adulte (néphropathie chronique) | En attente | |||
| Vemlidy | ténofovir alafénamide | Hépatite B chronique | Reimburse with clinical criteria and/or conditions | Complete | September 28, 2017 | March 26, 2018 |
| Verkazia | Cyclosporine | Kératoconjonctivite vernale grave, pédiatrique (≥4 ans) | Reimburse with clinical criteria and/or conditions | Complete | May 22, 2019 | November 18, 2019 |
| Vesicare | Succinate de solifénacine | Vessie hyperactive | List with clinical criteria and/or conditions | Complete | January 5, 2009 | June 17, 2009 |
| Vesicare | Succinate de solifénacine | Vessie hyperactive | Do not list | Complete | July 24, 2006 | January 24, 2007 |
| VesiFlow | Succinate de solifénacine / chlorhydrate de tamsulosine | hyperplasie bénigne de la prostate (HBP)-associée à des symptômes des voies urinaires inférieures | Withdrawn | April 6, 2015 | ||
| VFEND | Voriconazole | Candidémie | List with clinical criteria and/or conditions | Complete | March 24, 2006 | October 25, 2006 |
| VFEND | Voriconazole | Aspergillose, invasive | List with clinical criteria and/or conditions | Complete | October 25, 2004 | April 14, 2005 |
| VFEND | Voriconazole | Aspergillose invasive | Withdrawn | August 24, 2004 | ||
| Viacoram | perindopril arginine / bésylate d’amlodipine | Hypertension essentielle | Reimburse with clinical criteria and/or conditions | Complete | May 2, 2016 | October 26, 2016 |
| Viberzi | éluxadoline | Syndrome du côlon irritable avec diarrhée | Do not reimburse | Complete | February 23, 2018 | August 24, 2018 |
| Victoza | Liraglutide | Diabète de type 2 | Do not list | Complete | November 29, 2010 | September 28, 2011 |
| Victoza | Liraglutide | Diabète de type 2 | Withdrawn | October 20, 2016 | ||
| Victrelis | Bocéprévir | Hépatite C chronique | List with clinical criteria and/or conditions | Complete | May 3, 2011 | October 24, 2011 |
| Victrelis | Bocéprévir | Hépatite C chronique | List with criteria/condition | Complete | December 21, 2012 | June 13, 2013 |
| Victrelis | Boceprevir | Hepatitis C infection, chronic | List with criteria/condition | Complete | February 19, 2013 | June 13, 2013 |
| Viibryd | vilazodone | Dépression, trouble dépressif caractérisé | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | NotFiled | ||
| Vimizim | élosulfase alfa | Mucopolysaccharidose IVA (syndrome de Morquio) | Do not list | Complete | August 5, 2014 | March 25, 2015 |
| Vimizim | Élosulfase alfa | Mucopolysaccharidose IVA (syndrome de Morquio A) | Reimburse with clinical criteria and/or conditions | Complete | November 10, 2015 | May 20, 2016 |
| Vimpat | Lacosamide | Crises épileptiques partielles | List with clinical criteria and/or conditions | Complete | October 25, 2010 | April 25, 2011 |
| Viread | Fumarate de ténofovir disoproxil | Infection par le VIH | List with clinical criteria and/or conditions | Complete | August 11, 2005 | March 15, 2006 |
| Viread | Fumarate de ténofovir disoproxil | Infection par le VIH | Do not list | Complete | February 23, 2004 | August 25, 2004 |
| Viread | Fumarate de ténofovir disoproxil | Hépatite B chronique | List with clinical criteria and/or conditions | Complete | October 2, 2008 | March 18, 2009 |
| Viread | Fumarate de ténofovir disoproxil | Infection par le VIH | Complete | July 7, 2008 | ||
| Visanne | Dienogest | Douleur pelvienne liée à l’endométriose | List with clinical criteria and/or conditions | Complete | October 18, 2011 | April 19, 2012 |
| Volibris | Ambrisentan | Hypertension pulmonaire (classes II et III de l'OMS) | List with clinical criteria and/or conditions | Complete | July 9, 2008 | December 17, 2008 |
| Vonvendi | facteur de von Willebrand recombinant | Le traitement et la prise en charge périopératoire de l’adulte atteint de la maladie de von Willebrand | Active | April 29, 2020 | ||
| Vosevi | Sofosbuvir/velpatasvir/voxilaprévir | Hépatite C chronique | Reimburse with clinical criteria and/or conditions | Complete | July 28, 2017 | January 23, 2018 |
| VPRIV | Vélaglucérase alfa | Maladie de Gaucher | List with clinical criteria and/or conditions | Complete | October 28, 2010 | April 25, 2011 |
| Vyndaqel | Tafamidis | Amyloïdose à transthyrétine | Reimburse with clinical criteria and/or conditions | Complete | July 4, 2019 | February 19, 2020 |
| Vyvanse | Dimésylate de lisdexamfétamine | Trouble déficitaire de l’attention avec hyperactivité | Do not list | Complete | July 10, 2009 | December 18, 2009 |
| Vyzulta | Latanoprostène bunod | Glaucome à angle ouvert ou hypertension oculaire | Reimburse with clinical criteria and/or conditions | Complete | November 23, 2018 | July 24, 2019 |
| Xarelto | Rivaroxaban | Accidents thromboemboliques (veineux), embolie pulmonaire | List with criteria/condition | Complete | May 6, 2013 | March 26, 2014 |
| Xarelto | Rivaroxaban | Thromboembolie (veineuse), prévention | Complete | June 24, 2011 | ||
| Xarelto | Rivaroxaban | Thromboembolie (veineuse), prévention | List with clinical criteria and/or conditions | Complete | May 7, 2008 | December 17, 2008 |
| Xarelto | Rivaroxaban | Prévention de l’accident vasculaire cérébral et d'évènements cardiovasculaires causés par la coronopathie ou la maladie artérielle périphérique | Reimburse with clinical criteria and/or conditions | Complete | May 24, 2018 | November 20, 2018 |
| Xarelto | Rivaroxaban | Traitement de la thrombose veineuse profonde sans embolie pulmonaire symptomatique | List with clinical criteria and/or conditions | Complete | February 27, 2012 | August 16, 2012 |
| Xarelto | Rivaroxaban | Prévention de l’accident vasculaire cérébral en présence de fibrillation auriculaire | List with clinical criteria and/or conditions | Complete | October 21, 2011 | April 19, 2012 |
| Xarelto | Rivaroxaban | Traitement de la thrombose veineuse profonde sans embolie pulmonaire symptomatique | Complete | October 10, 2012 | ||
| Xarelto | Rivaroxaban | Prévention de l’accident vasculaire cérébral en présence de fibrillation auriculaire | List with clinical criteria and/or conditions | Complete | March 18, 2013 | July 18, 2013 |
| Xeljanz | Tofacitinib | Polyarthrite rhumatoïde | List with criteria/condition | Complete | May 5, 2014 | April 17, 2015 |
| Xeljanz | tofacitinib | Colite ulcéreuse | Reimburse with clinical criteria and/or conditions | Complete | June 27, 2018 | February 27, 2019 |
| Xeljanz | Tofacitinib | Polyarthrite psoriasique | Cancelled | |||
| Xeomin | Neurotoxine de Clostridium botulinum de type A sans protéines complexantes | Blépharospasme | List in a similar manner | Complete | June 12, 2009 | December 16, 2009 |
| Xeomin | Neurotoxine de Clostridium botulinum de type A sans protéines complexantes | Dystonie cervicale | List in a similar manner | Complete | June 12, 2009 | December 16, 2009 |
| Xeomin | Neurotoxine de Clostridium botulinum de type A sans protéines complexantes | Spasticité consécutive à un accident vasculaire cérébral | Do not list | Complete | June 12, 2009 | December 16, 2009 |
| Xermelo | télotristat | syndrome carcinoïde | Do not reimburse | Complete | September 27, 2018 | June 26, 2019 |
| Xgeva | Denosumab (demande pour régimes d'assurance) | Prévention des complications squelettiques causées par des métastases osseuses découlant du cancer du sein | List with clinical criteria and/or conditions | Complete | July 31, 2015 | February 25, 2016 |
| Xgeva | Denosumab (demande de régimes d'assurance médicaments) | Prévention des complications osseuses dues aux métastases osseuses d’une tumeur solide (sauf le cancer du sein ou de la prostate), y compris le cancer du poumon non à petites cellules | List with clinical criteria and/or conditions | Complete | July 31, 2015 | March 23, 2016 |
| XGEVA | Denosumab | prévention des complications osseuses dues aux métastases osseuses d’une tumeur solide | List with clinical criteria and/or conditions | Complete | June 6, 2011 | November 16, 2011 |
| Xiaflex | Collagénase de Clostridium histolyticum | Maladie de Dupuytren avec cordon palpable | List with criteria/condition | Complete | August 30, 2012 | March 27, 2013 |
| XigDuo | dapagliflozin/metformin hydrochloride | Diabète de type 2 | Reimburse with clinical criteria and/or conditions | Active | January 7, 2016 | July 20, 2016 |
| Zytram XL | Chlorhydrate de tramadol | Douleur aigüe | Withdrawn | November 3, 2006 | ||
| Zytram XL | Chlorhydrate de tramadol | Douleur aigüe | Do not list | Complete | March 15, 2007 | September 26, 2007 |
| Xolair | Omalizumab | Asthme sévère persistant | Cancelled | April 18, 2005 | ||
| Xolair | Omalizumab | Asthme sévère persistant | Do not list | Complete | October 13, 2005 | March 7, 2006 |
| Xolair | Omalizumab (Déposé par un régime d’assurance médicaments) | Asthme grave persistent | Reimburse with clinical criteria and/or conditions | Complete | November 18, 2015 | May 18, 2016 |
| Xolair | Omalizumab | Urticaire, idiopathique chronique | List with clinical criteria and/or conditions | Complete | September 22, 2014 | May 7, 2015 |
| Xultophy | insuline dégludec et liraglutide | Diabète sucré de type 2 | Reimburse with clinical criteria and/or conditions | Complete | January 30, 2019 | October 24, 2019 |
| Xyrem | Oxybate de sodium | Narcolepsie | Do not list | Complete | July 9, 2008 | January 28, 2009 |
| Xyrem | Oxybate de sodium | Narcolepsie | Withdrawn | August 29, 2007 | ||
| Yasmin | Drospirénone et éthinylestradiol | Contraceptif oral | List | Complete | January 20, 2005 | June 16, 2005 |
| Zavesca | Miglustat | Maladie de Gaucher | Do not list | Complete | May 13, 2004 | November 24, 2004 |
| Zaxine | Rifaximine | Encéphalopathie hépatique | List with criteria/condition | Complete | August 5, 2014 | April 16, 2015 |
| Zeldox | Chlorhydrate de ziprasidone | Schizophrénie et troubles psychotiques apparentés | List with clinical criteria and/or conditions | Complete | January 10, 2008 | August 14, 2008 |
| Zenhale | Mométasone et formotérol | Asthme, traitement d'entretien (adultes et enfants de 12 ans ou plus) | List with clinical criteria and/or conditions | Complete | June 6, 2012 | December 19, 2012 |
| Zepatier | Elbasvir / grazoprévir | Hépatite C chronique | Reimburse with clinical criteria and/or conditions | Complete | October 27, 2015 | May 19, 2016 |
| Zeposia | ozanimod | sclérose en plaques cyclique | Active | August 25, 2020 | ||
| Zinbryta | Daclizumab bêta | Sclérose en plaques cyclique | Reimburse with clinical criteria and/or conditions | Complete | December 20, 2016 | June 20, 2017 |
| Zolgensma | onasemnogène abéparvovec | amyotrophie spinale, enfant | Active | June 25, 2020 | ||